<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with OASIS Tables v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing-oasis-article1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="publisher-id">IENZ</journal-id><journal-id journal-id-type="publisher-id">ienz20</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6352947</article-id><article-id pub-id-type="doi">10.1080/14756366.2018.1564288</article-id><article-id pub-id-type="publisher-id">1564288</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Virtual design of novel <italic>Plasmodium falciparum</italic> cysteine protease falcipain-2 hybrid lactone&#x02013;chalcone and isatin&#x02013;chalcone inhibitors probing the S2 active site pocket</article-title><alt-title alt-title-type="running-authors">K. N&#x02019;G. P. G. Allangba et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Allangba</surname><given-names>Koffi N&#x02019;Guessan Placide Gabin</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Keita</surname><given-names>M&#x000e9;lalie</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kre N&#x02019;Guessan</surname><given-names>Raymond</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Megnassan</surname><given-names>Eugene</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref><xref ref-type="aff" rid="AF0002">
<sup>b</sup>
</xref><xref ref-type="aff" rid="AF0003">
<sup>c</sup>
</xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><name><surname>Frecer</surname><given-names>Vladimir</given-names></name><xref ref-type="aff" rid="AF0003">
<sup>c</sup>
</xref><xref ref-type="aff" rid="AF0004">
<sup>d</sup>
</xref><xref ref-type="aff" rid="AF0005">
<sup>e</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Miertus</surname><given-names>Stanislav</given-names></name><xref ref-type="aff" rid="AF0003">
<sup>c</sup>
</xref><xref ref-type="aff" rid="AF0005">
<sup>e</sup>
</xref><xref ref-type="aff" rid="AF0006">
<sup>f</sup>
</xref></contrib><aff id="AF0001">
<label>a</label>
<institution>Laboratoire de Physique Fondamentale et Appliqu&#x000e9;e (LPFA), University of Abobo Adjam&#x000e9; (now Nangui Abrogoua)</institution>, Abidjan, <country>C&#x000f4;te d&#x02019;Ivoire</country>; </aff><aff id="AF0002">
<label>b</label>
<institution>Laboratoire de Chimie Organique Structurale et Th&#x000e9;orique, University of Cocody (now Felix Houphou&#x000eb;t Boigny)</institution>, Abidjan, <country>C&#x000f4;te d'Ivoire</country>; </aff><aff id="AF0003">
<label>c</label>
<institution>ICS-UNIDO</institution>, Trieste, <country>Italy</country>; </aff><aff id="AF0004">
<label>d</label>
<institution>Faculty of Pharmacy, Comenius University in Bratislava</institution>, Bratislava, <country>Slovakia</country>; </aff><aff id="AF0005">
<label>e</label>
<institution>International Centre for Applied Research and Sustainable Technology</institution>, Bratislava, <country>Slovakia</country>; </aff><aff id="AF0006">
<label>f</label>
<institution>Faculty of Natural Sciences, University of SS. Cyril and Methodius</institution>, Trnava, <country>Slovakia</country>
</aff></contrib-group><author-notes><corresp id="AN0001"><bold>CONTACT</bold> Eugene Megnassan <email>megnase@yahoo.com</email><institution>LPFA, UFR SFA, University Nangui Abrogoua</institution>, <addr-line>02&#x02009;BP 801</addr-line>, Abidjan02, <country>C&#x000f4;te D&#x02019;Ivoire</country></corresp></author-notes><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>30</day><month>1</month><year>2019</year></pub-date><volume>34</volume><issue>1</issue><fpage seq="54">547</fpage><lpage>561</lpage><history><date date-type="received"><day>24</day><month>10</month><year>2018</year></date><date date-type="rev-recd"><day>17</day><month>12</month><year>2018</year></date><date date-type="accepted"><day>20</day><month>12</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2019 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="ienz-34-1564288.pdf"/><abstract><title>Abstract</title><p>We report computer-aided design of new lactone&#x02013;chalcone and isatin&#x02013;chalcone (HLCIC) inhibitors of the falcipain-2 (<italic>Pf</italic>FP-2). 3D models of 15 FP-2:HLCIC1-15 complexes with known observed activity (<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>) were prepared to establish a quantitative structure&#x02013;activity (QSAR) model and linear correlation between relative Gibbs free energy of enzyme:inhibitor complex formation (&#x00394;&#x00394;<italic>G</italic>
<sub>com</sub>) and <italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>: p<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>&#x02009;=&#x02009;&#x02212;0.0236&#x02009;&#x000d7;&#x02009;&#x00394;&#x00394;<italic>G</italic>
<sub>com</sub>+5.082(#); <italic>R</italic>
<sup>2</sup>&#x02009;=&#x02009;0.93. A 3D pharmacophore model (PH4) derived from the QSAR directed our effort to design novel HLCIC analogues. During the design, an initial virtual library of 2621440 HLCIC was focused down to 18288 drug-like compounds and finally, PH4 screened to identify 81 promising compounds. Thirty-three others were added from an intuitive substitution approach intended to fill better the enzyme S2 pocket. One hundred and fourteen theoretical IC<sub>50</sub> (<italic>IC</italic>
<sub>50</sub>
<sup>pre)</sup> values were predicted by means of (#) and their pharmacokinetics (ADME) profiles. More than 30 putative HLCICs display <italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> 100 times superior to that of the published most active training set inhibitor HLCIC1.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Falcipain-2</kwd><kwd>Plasmodium falciparum</kwd><kwd>molecular modelling</kwd><kwd>QSAR model</kwd><kwd>pharmacophore</kwd><kwd>virtual library</kwd><kwd>pharmacokinetics</kwd></kwd-group><funding-group><award-group><funding-source><named-content content-type="funder-name">Slovak Research and Development Agency</named-content></funding-source><award-id>APVV-15&#x02013;0111</award-id><award-id>APVV-14&#x02013;0294</award-id><award-id>APVV-17&#x02013;0239</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">Ministry of Education and Slovak Academy of Sciences</named-content></funding-source><award-id>VEGA 1/0228/17</award-id></award-group><funding-statement>Financial support from the Slovak Research and Development Agency [APVV-15&#x02013;0111, APVV-14&#x02013;0294 and APVV-17&#x02013;0239] and Granting Agency of Slovak Ministry of Education and Slovak Academy of Sciences [VEGA 1/0228/17], are gratefully acknowledged.</funding-statement></funding-group><counts><fig-count count="12"/><table-count count="12"/><page-count count="15"/><word-count count="11880"/></counts></article-meta></front><body><sec id="s0001"><label>1.</label><title>Introduction</title><p>Malaria remains the main cause of death all over the world and we are unable to reverse this sad morbidity statistic. Indeed, during the year 2015, 212 million cases of malaria and 429 thousand death cases were reported by the WHO<xref rid="CIT0001" ref-type="bibr">
<sup>1</sup>
</xref>. <italic>Plasmodium falciparum</italic> (<italic>Pf</italic>), the most virulent causative agent of malaria, is developing resistance rapidly so that the future of the Artemisinin Combined Therapy (ACT, available since 2006) is compromised<xref rid="CIT0002" ref-type="bibr">
<sup>2</sup>
</xref>. For almost a decade the development of novel antimalarials concerned mainly ACT, as recently exemplified by introduction of the combination of artemether and lumefantrine referred to as <italic>novamether</italic>
<xref rid="CIT0003" ref-type="bibr">
<sup>3</sup>
</xref>. Luckily, this alarming dark picture has been illuminated by the reported new antimalarial candidates<xref rid="CIT0004" ref-type="bibr">
<sup>4&#x02013;6</sup>
</xref>. Relatively low level of structural knowledge of novel and validated pharmacological targets of the <italic>Pf</italic> on one side and the lack of inhibition pharmacophores on the other, remain the drawbacks of antimalarial drug design (ADD) and development. One of the recent ADD strategies was to design hybrids molecules containing artemisinin (ART) or other antimalarial combined with another structural fragment<xref rid="CIT0006" ref-type="bibr">
<sup>6&#x02013;8</sup>
</xref>. Falcipains have drawn the attention of ADD due to their important role in the haemoglobin degradation (along with plasmepsins) while their inhibition is lethal to the <italic>Pf</italic>
<xref rid="CIT0009" ref-type="bibr">
<sup>9&#x02013;11</sup>
</xref>. Lactone&#x02013;chalcone and isatin&#x02013;chalcone (HLCIC) hybrid molecules have been mentioned in this context, their experimental FP-2 inhibitory activities were reported<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref>. They essentially target the bipartite motifs of falcipain-2 (FP-2) and falcipain-3 (FP-3), the papain-family cysteine proteases of <italic>Pf</italic>, which are involved in the degradation of host&#x02019;s haemoglobin within the food vacuole during the blood-stage of the parasite<xref rid="CIT0013" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>,</sup>
<xref rid="CIT0014" ref-type="bibr">
<sup>14</sup>
</xref>. Due to their specific features, falcipains represent promising targets for the development of next-generation antimalarials<xref rid="CIT0010" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref rid="CIT0014" ref-type="bibr">
<sup>14</sup>
</xref>.</p><p>In this work, we design new analogues of HLCIC starting from a series of 15 known HLCIC hybrids with determined experimental inhibition potencies (<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>), which were used as a training set<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref>. We build on our design and new analogue activity prediction relies on a reliable descriptor, namely standard Gibbs free energy (GFE) of enzyme:inhibitor (E:I) complex formation (&#x00394;<italic>G</italic>
<sub>com</sub>), quantitative structure&#x02013;activity relationships (QSAR), 3D structural model of the FP-2 and analysis of the inhibitor&#x02013;enzyme interactions. Relative changes in the GFE of E:I complex formation were computed in order to build a linear regression QSAR model utilising the published <italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>
<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref>. Each complex was carefully built by <italic>in situ</italic> modification of the reference crystal structure of FP-2 (3BPF)<xref rid="CIT0015" ref-type="bibr">
<sup>15</sup>
</xref> in complex with epoxysuccinate E64 (<xref ref-type="fig" rid="F0001">Figure 1</xref>). The 3D models of inhibitors bound to FP-2, QSAR and pharmacophore (PH4) models derived for the training set compounds provided the necessary structural information needed to improve inhibitor interactions at pockets S1, S2, and S3 of the FP-2 active site. Screening of designed virtual library (VL) of analogues by the PH4 led to the identification of potent HLCIC, which are predicted to be hundreds of times more potent than the best training set inhibitor HLCIC1 (<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>&#x02009;=&#x02009;6.8&#x02009;&#x000b5;M). </p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>(a) Molecular structure of epoxysuccinate E64 with indicated P1, P2, and P3 positions. (b) 3D depiction of E64 interactions with the FP-2 active site residues involving residues that occupy S1, S2, and S3 pockets of the active site<xref rid="CIT0015" ref-type="bibr">
<sup>15</sup>
</xref>.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1564288_F0001_C"/></fig></sec><sec id="s0002"><label>2.</label><title>Materials and methods</title><p>The methodology of computer-assisted molecular design based on 3D models of E:I complexes and QSAR analysis of a training set of known inhibitors has been successfully applied to optimisation of antiviral, antibacterial, and anti-protozoan compounds including peptidomimetic, hydroxynaphthoic, thymidine, triclosan, pyrrolidine carboxamide derivatives, peptidic, and ART hybrids inhibitors<xref rid="CIT0008" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>,</sup>
<xref rid="CIT0016" ref-type="bibr">
<sup>16&#x02013;26</sup>
</xref>. The workflow shown in <xref ref-type="fig" rid="F0002">Figure 2</xref> describes the series of steps of virtual design of novel HLCIC analogues.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Workflow describing the multistep approach to virtually designed novel HLCIC analogues with higher predicted potencies against the FP-2 of <italic>Pf</italic>.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1564288_F0002_C"/></fig><sec id="s0003"><label>2.1.</label><title>Training sets</title><p>The chemical structures of the training set compounds comprising 15 HLCIC hybrids and their experimental biological activities (IC<sub>50</sub>
<sup>exp</sup>&#x02009;=&#x02009;6.8&#x02013;90&#x02009;&#x000b5;M) are taken from the literature<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref>. The IC<sub>50</sub>
<sup>exp</sup> values of the HLCIC compounds cover a relatively wide concentration range, which is needed to build a reliable QSAR model.</p></sec><sec id="s0004"><label>2.2.</label><title>Model building and calculation of binding affinity</title><p>Molecular modelling was carried out for the E:I (FP-2:HLCIC) complexes, the free enzyme FP-2, and the free HLCIC inhibitors starting from the high-resolution crystal structure of FP-2 co-crystallised with epoxysuccinate E64 inhibitor (<italic>PDB</italic> code 3BPF, resolution 2.9&#x02009;&#x000c5;) using Insight II molecular modelling program<xref rid="CIT0027" ref-type="bibr">
<sup>27</sup>
</xref>. Initially, all crystallographic waters were removed, then hydrogens were added to the residues of the FP-2 and FP-2:HLCIC complex with the protonisation/ionisation state corresponding to the pH of 7 keeping the N- and C-terminal groups neutral. Inhibitors were modelled from the 3BPF reference crystal structure by <italic>in situ</italic> modification of functional groups in the molecular scaffold of the endogenous E64 inhibitor. All rotatable bonds of the replacing fragments were subjected to an exhaustive conformational search coupled with a careful gradual energy-minimisation of the modified inhibitor and active-site residues of FP-2 located in the immediate vicinity (5&#x02009;&#x000c5; radius) in order to identify low-energy bound conformations of the modified inhibitors. The resulting low-energy structures of the E:I complexes were then carefully refined by energy-minimisation procedure of the entire complex to obtain stable structures of the binary FP-2:HLCIC complexes. The complete description of the computation of relative ligand binding affinity (&#x00394;&#x00394;<italic>G</italic>
<sub>com</sub>) is described in Ref. [<xref rid="CIT0025" ref-type="bibr">25</xref>]:
<disp-formula id="M0001"><label>(1)</label><alternatives><graphic xlink:href="IENZ_A_1564288_M0001.jpg" position="float" orientation="portrait"/><mml:math id="ID0EAAABJCBA"><mml:mrow><mml:mo>&#x00394;</mml:mo><mml:mo>&#x00394;</mml:mo><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mtext>com</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo>&#x00394;</mml:mo><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mtext>com</mml:mtext></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>I</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mo>&#x00394;</mml:mo><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mtext>com</mml:mtext></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mtext>ref</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo>&#x00394;</mml:mo><mml:mo>&#x00394;</mml:mo><mml:msub><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mtext>MM</mml:mtext></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mo>&#x00394;</mml:mo><mml:mo>&#x00394;</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mtext>vib</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo>&#x00394;</mml:mo><mml:mo>&#x00394;</mml:mo><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mtext>sol</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></disp-formula>
</p><p>The &#x00394;&#x00394;<italic>H</italic>
<sub>MM</sub> describes the relative enthalpic contribution to the GFE change corresponding to the intermolecular interactions in the E:I complex estimated by molecular mechanics (MM), &#x00394;&#x00394;<italic>G</italic>
<sub>sol</sub>, and &#x00394;&#x00394;<italic>TS</italic>
<sub>vib</sub> represent the relative solvation and vibrational entropy contributions to the GFE of the E:I complex formation, respectively.</p></sec><sec id="s0005"><label>2.3.</label><title>Molecular mechanics</title><p>Modelling of the inhibitors and their complexes were carried out in all-atom representation using atomic parameters and charges of the class II consistent force field CFF91<xref rid="CIT0022" ref-type="bibr">
<sup>22</sup>
</xref>. A dielectric constant of 4 was used for all MM calculations in order to take into account the dielectric shielding effect in proteins. Minimisations of the E:I complexes, free E and I were carried out by relaxing the structures gradually, starting with added hydrogen atoms, continued with residue side chain heavy atoms and followed by the protein backbone relaxation. Geometry optimisations were performed using the sufficient number of steepest descent and conjugate gradient iterative cycles and average gradient convergence criterion of 0.01&#x02009;kcal&#x000b7;mol<sup>&#x02212;1</sup>&#x000b7;&#x000c5;<sup>&#x02212;1</sup>.</p></sec><sec id="s0006"><label>2.4.</label><title>Solvation GFE</title><p>The electrostatic component of the solvation GFE, which includes also the effect of ionic strength of the solvent by solving the non-linear Poisson&#x02013;Boltzmann equation<xref rid="CIT0028" ref-type="bibr">
<sup>28</sup>
</xref>
<sup>,</sup>
<xref rid="CIT0029" ref-type="bibr">
<sup>29</sup>
</xref> was computed by the DelPhi module of the Discovery Studio (DS 2.5)<xref rid="CIT0030" ref-type="bibr">
<sup>30</sup>
</xref>. The program represents the solvent by a continuous medium of high dielectric constant (<italic>&#x003b5;</italic>
<sub>ro</sub>&#x02009;=&#x02009;80) and the solute as a charge distribution filling a low dielectric cavity (<italic>&#x003b5;</italic>
<sub>ri</sub>&#x02009;=&#x02009;4) with boundaries linked to the solute&#x02019;s molecular surface. The program numerically solves for the molecular electrostatic potential and reaction field around the solute using finite difference method. DelPhi calculations were done on a (235&#x02009;&#x000d7;&#x02009;235&#x02009;&#x000d7;&#x02009;235) cubic lattice grid for the E:I complexes and free E and on a (65&#x02009;&#x000d7;&#x02009;65&#x02009;&#x000d7;&#x02009;65) grid for the free I. Full coulombic boundary conditions were employed. Two subsequent focusing steps led to a similar final resolution of about 0.3&#x02009;&#x000c5; per grid unit at 70% filling of the grid by the solute. Physiological ionic strength of 0.145&#x02009;mol&#x000b7;dm<sup>&#x02212;3</sup>, atomic partial charges and radii defined in the CFF force field parameter set<xref rid="CIT0030" ref-type="bibr">
<sup>30</sup>
</xref> and a probe sphere radius of 1.4&#x02009;&#x000c5; were used. The electrostatic component of the Poisson&#x02013;Boltzmann solvation GFE was calculated as the reaction field energy<xref rid="CIT0021" ref-type="bibr">
<sup>21</sup>
</xref>
<sup>,</sup>
<xref rid="CIT0024" ref-type="bibr">
<sup>24</sup>
</xref>
<sup>,</sup>
<xref rid="CIT0029" ref-type="bibr">
<sup>29</sup>
</xref>
<sup>,</sup>
<xref rid="CIT0031" ref-type="bibr">
<sup>31</sup>
</xref>
<sup>,</sup>
<xref rid="CIT0032" ref-type="bibr">
<sup>32</sup>
</xref>.</p></sec><sec id="s0007"><label>2.5.</label><title>Interaction energy</title><p>The molecular mechanic interaction energy (<italic>E</italic>
<sub>int</sub>) calculation protocol available in DS 2.5<xref rid="CIT0030" ref-type="bibr">
<sup>30</sup>
</xref> was used to compute the non-bonded interactions (van der Walls and electrostatic interatomic potential terms) between two sets of atoms belonging either to the E or I in the E:I complexes. All pairs of interactions of the total enzyme&#x02013;inhibitor interaction energy were evaluated using CFF force field parameters with a relative permittivity of 4<xref rid="CIT0030" ref-type="bibr">
<sup>30</sup>
</xref>. In particular, the breakdown of <italic>E</italic>
<sub>int</sub> into contributions from individual active site residues allows a quantitative analysis, which permits identification of residues with the highest contribution to the ligand binding. It also helps with the identification of favourable structural modifications and suggests molecular moieties in the inhibitor structure which are primarily responsible for the biological activity of the compound<xref rid="CIT0022" ref-type="bibr">
<sup>22</sup>
</xref>.</p></sec><sec id="s0008"><label>2.6.</label><title>3D-QSAR pharmacophore generation</title><p>Pharmacophore (PH4) modelling assumes that a set of key structural features responsible for biological activity of the compound is recognised by the active site during receptor binding. In this work, the pharmacophore was prepared by the 3D-QSAR pharmacophore protocol of Catalyst HypoGen algorithm<xref rid="CIT0033" ref-type="bibr">
<sup>33</sup>
</xref> implemented in DS 2.5<xref rid="CIT0030" ref-type="bibr">
<sup>30</sup>
</xref>. Bound conformations of HLCIC inhibitors taken from the refined E:I complexes were considered for construction of the PH4. The top scoring pharmacophore hypothesis was prepared in three stages: constructive, subtractive, and optimisation step, from a set of most active HLCIC inhibitors. The inactive compounds served for the definition of excluded volume. During the PH4 generation, five features available in the HypoGen algorithm were used: hydrophobic aromatic (HYdAr), hydrophobic aliphatic (HYd), hydrogen-bond donor (HBD), acceptor (HBA), and ring aromatic (Ar) feature. Default values of the adjustable parameters were kept during the PH4 generation, except the uncertainty on the biological activity, which was reduced to 1.25 instead of 3. This adjustment modified the uncertainty interval of experimental activity from a wide span [<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>/3, 3&#x000d7;<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>] to a relatively narrow one] [4&#x000d7;<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>/5, 5&#x000d7;<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>/4], due to accuracy and homogeneity of the measured activities originating from the same laboratory<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref>. The top ten pharmacophores were generated with the number of missing features set to zero. Finally, the best PH4 model was selected. Generally, a PH4 model, as the one described here, can be used to estimate the p<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> of new analogues on the basis of their mapping to its features. In this study, priority was given to PH4 based screening of ADME focused VL of HLCIC analogues.</p></sec><sec id="s0009"><label>2.7.</label><title>ADME-related properties</title><p>Properties that determine the pharmacokinetics profile of a compound, besides octanol/water partitioning coefficient, aqueous solubility, blood/brain partition coefficient, Caco-2 cell permeability, serum protein binding, number of likely metabolic reactions and other 18 descriptors related to adsorption, distribution, metabolism and excretion (ADME properties) of the inhibitors were computed by the QikProp program<xref rid="CIT0034" ref-type="bibr">
<sup>34</sup>
</xref> based on the methods of Jorgensen<xref rid="CIT0035" ref-type="bibr">
<sup>35&#x02013;37</sup>
</xref>. According to these methods, experimental results of more than 710 compounds including about 500 drugs and related heterocycles, were correlated with computed physico-chemical descriptors, resulting in an accurate prediction of molecule&#x02019;s pharmacokinetic profile. Drug likeness (#stars) is represented by the number of descriptors that exceed the range of values determined for 95% of known drugs out of 24 selected descriptors computed by the QikProp<xref rid="CIT0034" ref-type="bibr">
<sup>34</sup>
</xref>. Drug-likeness was used as the global compound selection criterion related to ADME properties. The selected ADME descriptors were calculated from 3D structures of compounds considered. They were used to assess the pharmacokinetics profile of designed compounds and served also for the VL focusing.</p></sec><sec id="s0010"><label>2.8.</label><title>Virtual combinatory library generation</title><p>The analogue model building was performed with Molecular Operating Environment (MOE) program<xref rid="CIT0038" ref-type="bibr">
<sup>38</sup>
</xref>. The library of analogues was enumerated by attaching R-groups (fragments, building blocks) onto HLCIC scaffold using the Quasar CombiDesign module of MOE<xref rid="CIT0038" ref-type="bibr">
<sup>38</sup>
</xref>. Reagents and chemicals considered in this paper were selected from the directories of chemicals available from the commercial sources. Each analogue was built as a neutral molecule in the MOE program<xref rid="CIT0038" ref-type="bibr">
<sup>38</sup>
</xref>, its geometry was refined by MM optimisation through smart minimiser of DS 2.5<xref rid="CIT0030" ref-type="bibr">
<sup>30</sup>
</xref> meeting high convergence criteria (threshold on energy difference of 10<sup>&#x02212;4&#x02009;</sup>kcal&#x000b7;mol<sup>&#x02212;1</sup> and root mean square deviation (RMSD) of 10<sup>&#x02212;5&#x02009;</sup>&#x000c5;), dielectric constant of 4, using class II consistent force field CFF<xref rid="CIT0039" ref-type="bibr">
<sup>39</sup>
</xref>.</p></sec><sec id="s0011"><label>2.9.</label><title>ADME-based library focusing</title><p>Twenty-four pharmacokinetics-related molecular descriptors available in QikProp<xref rid="CIT0034" ref-type="bibr">
<sup>34</sup>
</xref>, which characterise a wide spectrum of molecular properties as described in <xref ref-type="sec" rid="s0009">Section 2.7</xref>, were used. Optimum ranges of these 24 descriptors were defined in terms of upper and lower bounds according to QikProp<xref rid="CIT0034" ref-type="bibr">
<sup>34</sup>
</xref>. Among them predicted drug-likeness (#stars, <xref ref-type="sec" rid="s0009">Section 2.7</xref>) was used to retain drug-like HLCIC analogues in the focused VL.</p></sec><sec id="s0012"><label>2.10.</label><title>Pharmacophore-based library focusing</title><p>The pharmacophore model (PH4) described in <xref ref-type="sec" rid="s0008">Section 2.6</xref> was derived from the bound conformations of HLCIC at the active site of FP-2. The enumerated and ADME-focused VL was further evaluated by using the pharmacophore mapping protocol available of DS 2.5<xref rid="CIT0030" ref-type="bibr">
<sup>30</sup>
</xref>. Within this protocol, each generated conformer of the analogues was geometry optimised by means of the CFF force field for a maximum of 500 energy minimisation steps and subsequently aligned and mapped to the PH4 model in order to select the top ranking overlaps. Twenty best-fitting inhibitor conformers were saved and clustered into 10 conformational families according to their mutual RMSD by Jarvis-Patrick complete linkage clustering method<xref rid="CIT0040" ref-type="bibr">
<sup>40</sup>
</xref>. The best representative of each cluster was considered for the virtual screening of analogues. Only those analogues mapping to all PH4 features were retained for the <italic>in silico</italic> screening.</p></sec><sec id="s0013"><label>2.11.</label><title>In silico screening</title><p>The conformer with the best match to the PH4 pharmacophore in each cluster of the focused library subset was selected for <italic>in silico</italic> screening by the complexation QSAR model. The relative GFE of E:I complex formation in water &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> was computed for each selected new analogue and then used for prediction of FP-2 inhibitory potencies (<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>) of the focused VL of HLCIC analogues by inserting this parameter into the target-specific scoring function. The scoring function, which is specific for the FP-2 receptor of <italic>Pf</italic> inhibition, is given in <xref ref-type="disp-formula" rid="M0002">Equation (2)</xref>, was parameterised using the QSAR model of training set of HLCIC inhibitors<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref>.
<disp-formula id="M0002"><label>(2)</label><alternatives><graphic xlink:href="IENZ_A_1564288_M0002.jpg" position="float" orientation="portrait"/><mml:math id="ID0EAAAAACBA"><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi>I</mml:mi><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:msup><mml:mrow/><mml:mrow><mml:mtext>pre</mml:mtext></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mo>&#x02009;</mml:mo><mml:mtext>log</mml:mtext><mml:mo>&#x02009;</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mi>I</mml:mi><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:msup><mml:mrow/><mml:mrow><mml:mtext>pre</mml:mtext></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mi mathvariant="normal">a</mml:mi><mml:mo>&#x000b7;</mml:mo><mml:mo>&#x00394;</mml:mo><mml:mo>&#x00394;</mml:mo><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mtext>com</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="normal">b</mml:mi></mml:mrow></mml:math></alternatives></disp-formula>
</p></sec></sec><sec id="s0014"><label>3.</label><title>Results and discussion</title><p>A series of 18 [15 training set HLCIC and 3 validation set (VS) HLCIV] of HLCIC inhibitors and their experimental activities (<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>) from the same laboratory<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref> were selected (<xref rid="t0001" ref-type="table">Table 1</xref>). These activities cover a relatively wide range 6.8&#x02009;&#x000b5;M &#x02264; <italic>IC</italic>
<sub>50</sub>
<sup>exp</sup> &#x02264; 90&#x02009;&#x000b5;M and allowed building of a valid QSAR model.</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Training set (HLCIC) and validation set (HLCIV) of FP-2 inhibitors<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref> used in the preparation of QSAR model of inhibitor binding to the FP-2 of <italic>Pf</italic>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th colspan="8" align="center"><inline-graphic xlink:href="IENZ_A_1564288_ILG0001_B.gif" content-type="black-white"/>Chalcone scaffold<hr/></th></tr><tr><th colspan="4" align="center"><inline-graphic xlink:href="IENZ_A_1564288_ILG0002_B.gif" content-type="black-white"/>linker-isatin (-lki)<hr/></th><th colspan="4" align="center"><inline-graphic xlink:href="IENZ_A_1564288_ILG0003_B.gif" content-type="black-white"/>linker-lactone (-lkl)<hr/></th></tr><tr><th align="left">Training set</th><th align="center"><italic>R</italic><sub>1</sub></th><th align="center"><italic>R</italic><sub>2</sub></th><th align="center"><italic>R</italic><sub>3</sub></th><th align="center"><italic>R</italic><sub>4</sub></th><th align="center"><italic>R</italic><sub>5</sub></th><th align="center"><italic>R</italic><sub>6</sub></th><th align="center"><italic>IC</italic><sub>50</sub><sup>exp</sup>(&#x003bc;M)</th></tr></thead><tbody valign="top"><tr><td align="left">HLCIC1</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;H</td><td align="center">&#x02013;OMe</td><td align="center">H</td><td align="center">lki</td><td align="center">H</td><td align="char" char=".">6.80</td></tr><tr><td align="left">HLCIC2</td><td align="center">&#x02013;H</td><td align="center">&#x02013;H</td><td align="center">&#x02013;OMe</td><td align="center">H</td><td align="center">lki</td><td align="center">H</td><td align="char" char=".">10.29</td></tr><tr><td align="left">HLCIC3</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;OMe</td><td align="center">H</td><td align="center">lki</td><td align="center">H</td><td align="char" char=".">11.49</td></tr><tr><td align="left">HLCIC4</td><td align="center">&#x02013;H</td><td align="center">&#x02013;H</td><td align="center">&#x02013;OMe</td><td align="center">lki</td><td align="center">H</td><td align="center">H</td><td align="char" char=".">25.44</td></tr><tr><td align="left">HLCIC5</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;H</td><td align="center">&#x02013;OMe</td><td align="center">lki</td><td align="center">H</td><td align="center">H</td><td align="char" char=".">15.58</td></tr><tr><td align="left">HLCIC6</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;OMe</td><td align="center">lki</td><td align="center">H</td><td align="center">H</td><td align="char" char=".">90.47</td></tr><tr><td align="left">HLCIC7</td><td align="center">&#x02013;H</td><td align="center">&#x02013;H</td><td align="center">&#x02013;OMe</td><td align="center">H</td><td align="center">H</td><td align="center">lki</td><td align="char" char=".">10.84</td></tr><tr><td align="left">HLCIC8</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;OMe</td><td align="center">H</td><td align="center">H</td><td align="center">lkl</td><td align="char" char=".">28.50</td></tr><tr><td align="left">HLCIC9</td><td align="center">&#x02013;H</td><td align="center">&#x02013;H</td><td align="center">&#x02013;lki</td><td align="center">H</td><td align="center">H</td><td align="center">&#x02013;OMe</td><td align="char" char=".">15.89</td></tr><tr><td align="left">HLCIC10</td><td align="center">lki</td><td align="center">&#x02013;H</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">&#x02013;OMe</td><td align="char" char=".">15.96</td></tr><tr><td align="left">HLCIC11</td><td align="center">lki</td><td align="center">&#x02013;H</td><td align="center">H</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;H</td><td align="center">&#x02013;OMe</td><td align="char" char=".">15.04</td></tr><tr><td align="left">HLCIC12</td><td align="center">lki</td><td align="center">H</td><td align="center">H</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;OMe</td><td align="char" char=".">15.33</td></tr><tr><td align="left">HLCIC13</td><td align="center">&#x02013;H</td><td align="center">lki</td><td align="center">H</td><td align="center">&#x02013;H</td><td align="center">&#x02013;H</td><td align="center">&#x02013;OMe</td><td align="char" char=".">9.91</td></tr><tr><td align="left">HLCIC14</td><td align="center">&#x02013;H</td><td align="center">lki</td><td align="center">H</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;H</td><td align="center">&#x02013;OMe</td><td align="char" char=".">10.61</td></tr><tr><td align="left">HLCIC15</td><td align="center">&#x02013;H</td><td align="center">lki</td><td align="center">H</td><td align="center">&#x02013;H</td><td align="center">&#x02013;H</td><td align="center">&#x02013;OMe</td><td align="char" char=".">16.73</td></tr><tr><td align="left">Validation set</td><td align="center"><italic>R</italic><sub>1</sub></td><td align="center"><italic>R</italic><sub>2</sub></td><td align="center"><italic>R</italic><sub>3</sub></td><td align="center"><italic>R</italic><sub>4</sub></td><td align="center"><italic>R</italic><sub>5</sub></td><td align="center"><italic>R</italic><sub>6</sub></td><td align="center"><italic>IC</italic><sub>50</sub><sup>exp</sup>(&#x003bc;M)</td></tr><tr><td align="left">HLCICV1</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;OMe</td><td align="center">H</td><td align="center">H</td><td align="center">&#x02013;lki</td><td align="char" char=".">16.62</td></tr><tr><td align="left">HLCICV2</td><td align="center">&#x02013;H</td><td align="center">&#x02013;H</td><td align="center">&#x02013;lki</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;OMe</td><td align="char" char=".">25.06</td></tr><tr><td align="left">HLCICV3</td><td align="center">&#x02013;H</td><td align="center">&#x02013;H</td><td align="center">&#x02013;lki</td><td align="center">&#x02013;OMe</td><td align="center">&#x02013;H</td><td align="center">&#x02013;OMe</td><td align="char" char=".">18.28</td></tr></tbody></table></table-wrap><sec id="s0015"><label>3.1.</label><title>Results</title><p>The relative GFE of E:I complex formation &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> was calculated for the FP-2: HLCIC complexes as described in <xref ref-type="sec" rid="s0002">Section 2</xref>. <xref rid="t0002" ref-type="table">Table 2</xref> shows GFE and their components (<xref ref-type="disp-formula" rid="M0001">Equation (1)</xref>). The &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> reflects the mutual affinity between the enzyme and the inhibitor. Since it is calculated via an approximate approach, the relevance of the binding model is evaluated by a linear regression with experimentally observed activity data (IC<sub>50</sub>
<sup>exp</sup>)<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref> (<xref ref-type="disp-formula" rid="M0002">Equation (2)</xref>), which led to a linear correlation and QSAR model for the training set of HLCIC inhibitors. Two correlation equations obtained for the GFE of E:I complex formation &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> (Equation (B)) and its enthalpic component &#x00394;&#x00394;<italic>H</italic>
<sub>MM</sub> (Equation (A)), respectively are presented in <xref rid="t0003" ref-type="table">Table 3</xref> with the relevant statistical data plotted in <xref ref-type="fig" rid="F0003">Figure 3</xref>. The relatively high values of the regression coefficient <italic>R</italic>
<sup>2</sup> and the Fischer <italic>F</italic>-test of the correlation involving &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> indicate that there is a strong relationship between the binding model and the experimental inhibitory potencies of the HLCIC.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>(left): Plot of correlation between p<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup> and relative enthalpic contribution to the GFE &#x00394;&#x00394;<italic>H</italic>
<sub>MM</sub>; (right) similar plot for relative complexation GFE &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> of the training set of HLCIC, all in kcal&#x000b7;mol<sup>&#x02212;1</sup>. Validation set data is shown in red colour.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1564288_F0003_C"/></fig><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>GFE of E:I complex formation (&#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> binding affinity) and its components for the training set of FP-2 inhibitors HLCIC1-15 and the validation set of inhibitors HLCIV1-3.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Training set<xref ref-type="table-fn" rid="TF1">
<sup>a</sup>
</xref></th><th align="center"><italic>M<sub>w</sub></italic><xref ref-type="table-fn" rid="TF2">
<sup>b</sup>
</xref></th><th align="center">&#x00394;&#x00394;<italic>H</italic><sub>MM</sub><xref ref-type="table-fn" rid="TF3">
<sup>c</sup>
</xref></th><th align="center">&#x00394;&#x00394;<italic>G</italic><sub>sol</sub><xref ref-type="table-fn" rid="TF4">
<sup>d</sup>
</xref></th><th align="center">&#x00394;&#x00394;<italic>TS</italic><sub>vib</sub><xref ref-type="table-fn" rid="TF5">
<sup>e</sup>
</xref></th><th align="center">&#x00394;&#x00394;<italic>G</italic><sub>com</sub><xref ref-type="table-fn" rid="TF6">
<sup>f</sup>
</xref></th><th align="center"><italic>IC</italic><sub>50</sub><sup>exp</sup>&#x02009;<xref ref-type="table-fn" rid="TF7">
<sup>g</sup>
</xref></th></tr></thead><tbody valign="top"><tr><td align="left">HLCIC1</td><td align="char" char=".">607</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">6.80</td></tr><tr><td align="left">HLCIC2</td><td align="char" char=".">577</td><td align="char" char=".">1.66</td><td align="char" char=".">&#x02212;0.39</td><td align="char" char=".">&#x02212;1.37</td><td align="char" char=".">2.64</td><td align="char" char=".">10.29</td></tr><tr><td align="left">HLCIC3</td><td align="char" char=".">637</td><td align="char" char=".">13.38</td><td align="char" char=".">&#x02212;4.50</td><td align="char" char=".">0.41</td><td align="char" char=".">8.47</td><td align="char" char=".">11.49</td></tr><tr><td align="left">HLCIC4</td><td align="char" char=".">577</td><td align="char" char=".">17.93</td><td align="char" char=".">&#x02212;3.63</td><td align="char" char=".">0.24</td><td align="char" char=".">14.06</td><td align="char" char=".">25.44</td></tr><tr><td align="left">HLCIC5</td><td align="char" char=".">607</td><td align="char" char=".">15.96</td><td align="char" char=".">&#x02212;2.93</td><td align="char" char=".">1.45</td><td align="char" char=".">11.57</td><td align="char" char=".">15.58</td></tr><tr><td align="left">HLCIC6</td><td align="char" char=".">637</td><td align="char" char=".">45.68</td><td align="char" char=".">&#x02212;3.75</td><td align="char" char=".">&#x02212;2.99</td><td align="char" char=".">44.92</td><td align="char" char=".">90.47</td></tr><tr><td align="left">HLCIC7</td><td align="char" char=".">577</td><td align="char" char=".">8.64</td><td align="char" char=".">&#x02212;3.59</td><td align="char" char=".">0.45</td><td align="char" char=".">4.60</td><td align="char" char=".">10.84</td></tr><tr><td align="left">HLCIC8</td><td align="char" char=".">570</td><td align="char" char=".">26.70</td><td align="char" char=".">5.21</td><td align="char" char=".">8.22</td><td align="char" char=".">23.69</td><td align="char" char=".">28.5</td></tr><tr><td align="left">HLCIC9</td><td align="char" char=".">577</td><td align="char" char=".">12.61</td><td align="char" char=".">&#x02212;5.21</td><td align="char" char=".">0.01</td><td align="char" char=".">7.39</td><td align="char" char=".">15.89</td></tr><tr><td align="left">HLCIC10</td><td align="char" char=".">577</td><td align="char" char=".">13.77</td><td align="char" char=".">&#x02212;6.83</td><td align="char" char=".">&#x02212;2.70</td><td align="char" char=".">9.64</td><td align="char" char=".">15.96</td></tr><tr><td align="left">HLCIC11</td><td align="char" char=".">607</td><td align="char" char=".">15.73</td><td align="char" char=".">&#x02212;5.84</td><td align="char" char=".">&#x02212;0.53</td><td align="char" char=".">10.43</td><td align="char" char=".">15.04</td></tr><tr><td align="left">HLCIC12</td><td align="char" char=".">637</td><td align="char" char=".">20.75</td><td align="char" char=".">&#x02212;5.80</td><td align="char" char=".">0.41</td><td align="char" char=".">14.54</td><td align="char" char=".">15.33</td></tr><tr><td align="left">HLCIC13</td><td align="char" char=".">577</td><td align="char" char=".">4.80</td><td align="char" char=".">&#x02212;2.49</td><td align="char" char=".">&#x02212;3.03</td><td align="char" char=".">5.34</td><td align="char" char=".">9.91</td></tr><tr><td align="left">HLCIC14</td><td align="char" char=".">607</td><td align="char" char=".">6.81</td><td align="char" char=".">&#x02212;1.14</td><td align="char" char=".">&#x02212;1.87</td><td align="char" char=".">7.55</td><td align="char" char=".">10.61</td></tr><tr><td align="left">HLCIC15</td><td align="char" char=".">637</td><td align="char" char=".">19.63</td><td align="char" char=".">&#x02212;4.51</td><td align="char" char=".">2.29</td><td align="char" char=".">12.83</td><td align="char" char=".">16.73</td></tr><tr><td align="left">Validation set</td><td><italic>M<sub>w</sub></italic><xref ref-type="table-fn" rid="TF2">
<sup>b</sup>
</xref></td><td>&#x00394;&#x00394;<italic>H</italic><sub>MM</sub><xref ref-type="table-fn" rid="TF3">
<sup>c</sup>
</xref></td><td>&#x00394;&#x00394;<italic>G</italic><sub>sol</sub><xref ref-type="table-fn" rid="TF4">
<sup>d</sup>
</xref></td><td>&#x00394;&#x00394;<italic>TS</italic><sub>vib</sub><xref ref-type="table-fn" rid="TF5">
<sup>e</sup>
</xref></td><td>&#x00394;&#x00394;<italic>G</italic><sub>com</sub><xref ref-type="table-fn" rid="TF6">
<sup>f</sup>
</xref></td><td>p<italic>IC</italic><sub>50</sub><sup>pre</sup>/p<italic>IC</italic><sub>50</sub><sup>exp</sup>&#x02009;<xref ref-type="table-fn" rid="TF8">
<sup>h</sup>
</xref></td></tr><tr><td align="left">HLCIV1</td><td align="char" char=".">637</td><td align="char" char=".">7.13</td><td align="char" char=".">0.29</td><td align="char" char=".">2.51</td><td align="char" char=".">4.91</td><td align="char" char=".">1.104</td></tr><tr><td align="left">HLCIV2</td><td align="char" char=".">637</td><td align="char" char=".">20.98</td><td align="char" char=".">&#x02212;4.83</td><td align="char" char=".">1.14</td><td align="char" char=".">15.01</td><td align="char" char=".">1.079</td></tr><tr><td align="left">HLCIV3</td><td align="char" char=".">607</td><td align="char" char=".">16.47</td><td align="char" char=".">&#x02212;5.97</td><td align="char" char=".">0.71</td><td align="char" char=".">9.78</td><td align="char" char=".">1.065</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>
<sup>a</sup>For the chemical structures of the HLCIC see <xref rid="t0001" ref-type="table">Table 1</xref>.</p></fn><fn id="TF2"><p>
<sup>b</sup>
<italic>M<sub>w</sub></italic> is the molecular mass of the inhibitor (g&#x000b7;mol<sup>&#x02212;1</sup>).</p></fn><fn id="TF3"><p>
<sup>c</sup>&#x00394;&#x00394;<italic>H</italic>
<sub>MM</sub> (kcal&#x000b7;mol<sup>&#x02212;1</sup>) is the relative enthalpic contribution to the GFE change of the E:I complex formation derived by MM: &#x00394;&#x00394;<italic>H</italic>
<sub>MM</sub>&#x02009;&#x02245;&#x02009;[<italic>E</italic>
<sub>tot</sub>{FP-2:HLCICx} &#x02212; <italic>E</italic>
<sub>tot</sub>{HLCICx}]&#x02009;&#x02212;&#x02009;[<italic>E</italic>
<sub>tot</sub>{FP-2:HLCIC1} &#x02212; <italic>E</italic>
<sub>tot</sub>{HLCIC1}] where <italic>E</italic>
<sub>tot</sub> is the MM total energy and HLCIC1 is the reference inhibitor.</p></fn><fn id="TF4"><p>
<sup>d</sup>&#x00394;&#x00394;<italic>G</italic>
<sub>sol</sub> (kcal&#x000b7;mol<sup>&#x02212;1</sup>) is the relative solvation contribution to GFE change of the E:I complex formation &#x00394;&#x00394;<italic>G</italic>
<sub>sol</sub> = [<italic>G</italic>
<sub>sol</sub>{FP-2:HLCICx} &#x02212; <italic>G</italic>
<sub>sol</sub>{HLCICx}]&#x02009;&#x02212;&#x02009;[<italic>G</italic>
<sub>sol</sub>{FP-2:HLCIC1} &#x02212; <italic>G</italic>
<sub>sol</sub> {HLCIC1}].</p></fn><fn id="TF5"><p>
<sup>e</sup>&#x00394;&#x00394;<italic>TS</italic>
<sub>vib</sub> (kcal&#x000b7;mol<sup>&#x02212;1</sup>) is the relative entropic contribution of the inhibitor to the GFE related to protease-inhibitor complex formation: &#x00394;&#x00394;<italic>TS</italic>
<sub>vib</sub> = [<italic>TS</italic>
<sub>vib</sub>{FP-2:HLCICx} &#x02212; <italic>TS</italic>
<sub>vib</sub> {HLCICx}]&#x02009;&#x02212;&#x02009;[<italic>TS</italic>
<sub>vib</sub> {FP-2:HLCIC1} &#x02212; <italic>TS</italic>
<sub>vib</sub> {HLCIC1}].</p></fn><fn id="TF6"><p>
<sup>f</sup>&#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> (kcal&#x000b7;mol<sup>&#x02212;1</sup>) is the relative GFE change of E:I complex formation: &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> &#x02245; &#x00394;&#x00394;<italic>H</italic>
<sub>MM</sub> + &#x00394;&#x00394;<italic>G</italic>
<sub>sol</sub> &#x02212; &#x00394;&#x00394;<italic>TS</italic>
<sub>vib</sub>.</p></fn><fn id="TF7"><p>
<sup>g</sup>
<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup> (&#x003bc;M) is the experimental half-maximal inhibitory concentration obtained from Ref. [<xref rid="CIT0012" ref-type="bibr">12</xref>].</p></fn><fn id="TF8"><p>
<sup>h</sup>Ratio of predicted and experimental half-maximal inhibition concentrations p<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>/p<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup> (where p<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>&#x02009;=&#x02009;&#x02212;log<sub>10</sub>
<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> was predicted from computed &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> using the regression equation (B) shown in <xref rid="t0003" ref-type="table">Table 3</xref>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Regression analysis of computed binding affinities &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub>, its enthalpic component &#x00394;&#x00394;<italic>H</italic>
<sub>MM</sub> and observed activity p<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup> = &#x02212;log<sub>10</sub>
<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>
<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref> of hybrid lactone&#x02013;chalcone and isatin&#x02013;chalcone HLCIC.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Statistical data of linear regression</th><th align="center">(A)</th><th align="center">(B)</th></tr></thead><tbody valign="top"><tr><td align="left"><inline-formula id="ilm0001"><alternatives><inline-graphic xlink:href="IENZ_A_1564288_ILM0001.gif"/><mml:math id="ID0EAABCIAAAWBBBA"><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi>I</mml:mi><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mtext>exp</mml:mtext><mml:mo>&#x02009;</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>0.0224</mml:mn><mml:mo>&#x000b7;</mml:mo><mml:mo>&#x00394;</mml:mo><mml:mo>&#x00394;</mml:mo><mml:msub><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mtext>MM</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>5</mml:mn><mml:mo>.</mml:mo><mml:mn>1372</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> (A)</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td></tr><tr><td align="left"><inline-formula id="ilm0002"><alternatives><inline-graphic xlink:href="IENZ_A_1564288_ILM0002.gif"/><mml:math id="ID0EAABCHAAAWBBBA"><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi>I</mml:mi><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mtext>exp</mml:mtext><mml:mo>&#x02009;</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>0.0236</mml:mn><mml:mo>&#x000b7;</mml:mo><mml:mo>&#x00394;</mml:mo><mml:mo>&#x00394;</mml:mo><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mtext>com</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>5.082</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> (B)</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td></tr><tr><td align="left">Number of compounds n</td><td align="center">15</td><td align="center">15</td></tr><tr><td align="left">Squared correlation coefficient of regression <italic>R</italic><sup>2</sup>&#x000a0;</td><td align="center">0.91</td><td align="center">0.93</td></tr><tr><td align="left">LOO cross-validated squared correlation coef. <italic>R</italic><sub>xv</sub><sup>2</sup></td><td align="center">0.90</td><td align="center">0.92</td></tr><tr><td align="left">Standard error of regression <italic>&#x003c3;</italic></td><td align="center">0.08</td><td align="center">0.07</td></tr><tr><td align="left">Statistical significance of regression, Fischer <italic>F</italic>-test</td><td align="center">139.1</td><td align="center">180.4</td></tr><tr><td align="left">Level of statistical significance <italic>&#x003b1;</italic></td><td align="center">&#x0003e;95%</td><td align="center">&#x0003e;95%</td></tr><tr><td align="left">Range of activities <italic>IC</italic><sub>50</sub><sup>exp</sup> (&#x000b5;M)</td><td colspan="2" align="char" char=".">6.8&#x02013;90.0</td></tr></tbody></table></table-wrap><p>The bound conformation of the most potent FP-2 inhibitor HLCIC1<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref> in this QSAR model is displayed in <xref ref-type="fig" rid="F0004">Figure 4</xref> (<xref rid="t0001" ref-type="table">Table 1</xref>). The enzyme&#x02013;inhibitor overall intermolecular interaction energy E<sub>int</sub> in FP-2:HLClCx complexes is listed in <xref rid="t0004" ref-type="table">Table 4</xref> along with its correlation between that energy with observed inhibitory potency (<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>) plotted in <xref ref-type="fig" rid="F0005">Figure 5</xref>. According to the statistical data in <xref rid="t0005" ref-type="table">Table 5</xref>, some 85% of the <italic>IC</italic>
<sub>50</sub>
<sup>exp</sup> variation is explained by E<sub>int</sub> drop while moving from the best active HLClC1 to the less active one HLClC6. The quality of this correlation opens the gate to a deeper analysis of the intermolecular interaction energy E<sub>int</sub> variation in light with structural requirement of FP-2 inhibition namely the active site pockets filling.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>(Top) 2D schematic interaction diagram of the most potent inhibitor HLCIC1 (<xref rid="t0001" ref-type="table">Table 1</xref>) at the active-site of FP-2 of <italic>Pf</italic>; (Middle, Bottom) 3D structure of the active-site with bound HLCIC1.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1564288_F0004_C"/></fig><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Plot of correlation between p<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup> and overall intermolecular interaction energy <italic>E</italic>
<sub>int</sub> in complexes FP-2:HLCIC<sub>x</sub>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1564288_F0005_B"/></fig><table-wrap id="t0004" orientation="portrait" position="float"><label>Table 4</label><caption><p>Enzyme&#x02013;inhibitor FP-2:HLCICx overall intermolecular interaction energy <italic>E</italic>
<sub>int</sub> (kcal&#x000b7;mol<sup>&#x02212;1</sup>).</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Training set<xref ref-type="table-fn" rid="TF9">
<sup>a</sup>
</xref></th><th align="center">E<sub>vdw</sub><xref ref-type="table-fn" rid="TF10">
<sup>b</sup>
</xref></th><th align="center">E<sub>ele</sub><xref ref-type="table-fn" rid="TF11">
<sup>c</sup>
</xref></th><th align="center">E<sub>int</sub><xref ref-type="table-fn" rid="TF12">
<sup>d</sup>
</xref></th><th align="center">&#x00394;E<sub>int</sub></th><th align="center">pIC<sub>50</sub><sup>exp</sup></th></tr></thead><tbody valign="top"><tr><td align="left">HLCIC1</td><td align="char" char=".">&#x02212;57.32</td><td align="char" char=".">&#x02212;2.07</td><td align="char" char=".">&#x02212;59.39</td><td align="char" char=".">0</td><td align="char" char=".">5.167</td></tr><tr><td align="left">HLCIC2</td><td align="char" char=".">&#x02212;54.43</td><td align="char" char=".">&#x02212;1.83</td><td align="char" char=".">&#x02212;56.26</td><td align="char" char=".">3.13</td><td align="char" char=".">4.987</td></tr><tr><td align="left">HLCIC3</td><td align="char" char=".">&#x02212;55.21</td><td align="char" char=".">&#x02212;1.53</td><td align="char" char=".">&#x02212;56.75</td><td align="char" char=".">2.64</td><td align="char" char=".">4.939</td></tr><tr><td align="left">HLCIC4</td><td align="char" char=".">&#x02212;48.41</td><td align="char" char=".">0.09</td><td align="char" char=".">&#x02212;48.31</td><td align="char" char=".">11.08</td><td align="char" char=".">4.594</td></tr><tr><td align="left">HLCIC5</td><td align="char" char=".">&#x02212;49.63</td><td align="char" char=".">&#x02212;0.11</td><td align="char" char=".">&#x02212;49.75</td><td align="char" char=".">9.64</td><td align="char" char=".">4.807</td></tr><tr><td align="left">HLCIC6</td><td align="char" char=".">&#x02212;39.08</td><td align="char" char=".">&#x02212;1.76</td><td align="char" char=".">&#x02212;40.85</td><td align="char" char=".">18.54</td><td align="char" char=".">4.043</td></tr><tr><td align="left">HLCIC7</td><td align="char" char=".">&#x02212;53.71</td><td align="char" char=".">&#x02212;1.40</td><td align="char" char=".">&#x02212;55.11</td><td align="char" char=".">4.28</td><td align="char" char=".">4.964</td></tr><tr><td align="left">HLCIC8</td><td align="char" char=".">&#x02212;48.53</td><td align="char" char=".">&#x02212;3.35</td><td align="char" char=".">&#x02212;51.88</td><td align="char" char=".">7.51</td><td align="char" char=".">4.545</td></tr><tr><td align="left">HLCIC9</td><td align="char" char=".">&#x02212;52.19</td><td align="char" char=".">0.32</td><td align="char" char=".">&#x02212;51.87</td><td align="char" char=".">7.52</td><td align="char" char=".">4.798</td></tr><tr><td align="left">HLCIC10</td><td align="char" char=".">&#x02212;48.93</td><td align="char" char=".">&#x02212;1.27</td><td align="char" char=".">&#x02212;50.21</td><td align="char" char=".">9.18</td><td align="char" char=".">4.796</td></tr><tr><td align="left">HLCIC11</td><td align="char" char=".">&#x02212;51.00</td><td align="char" char=".">&#x02212;1.62</td><td align="char" char=".">&#x02212;52.63</td><td align="char" char=".">6.76</td><td align="char" char=".">4.822</td></tr><tr><td align="left">HLCIC12</td><td align="char" char=".">&#x02212;52.05</td><td align="char" char=".">&#x02212;0.21</td><td align="char" char=".">&#x02212;52.26</td><td align="char" char=".">7.13</td><td align="char" char=".">4.814</td></tr><tr><td align="left">HLCIC13</td><td align="char" char=".">&#x02212;54.24</td><td align="char" char=".">0.68</td><td align="char" char=".">&#x02212;53.55</td><td align="char" char=".">5.84</td><td align="char" char=".">5.003</td></tr><tr><td align="left">HLCIC14</td><td align="char" char=".">&#x02212;57.01</td><td align="char" char=".">0.28</td><td align="char" char=".">&#x02212;56.73</td><td align="char" char=".">2.66</td><td align="char" char=".">4.974</td></tr><tr><td align="left">HLCIC15</td><td align="char" char=".">&#x02212;53.87</td><td align="char" char=".">0.10</td><td align="char" char=".">&#x02212;53.76</td><td align="char" char=".">5.63</td><td align="char" char=".">4.776</td></tr></tbody></table><table-wrap-foot><fn id="TF9"><p>
<sup>a</sup>For the chemical structures of the training set of inhibitors see <xref rid="t0001" ref-type="table">Table 1</xref>.</p></fn><fn id="TF10"><p>
<sup>b</sup>van der Walls component of non-bonded of interaction energy.</p></fn><fn id="TF11"><p>
<sup>c</sup>Electrostatic component of non-bonded interaction energy.</p></fn><fn id="TF12"><p>
<sup>d</sup>
<italic>E</italic>
<sub>int</sub> is the interaction energy of two sets of atoms, one set represents residues of the FP-2 the other the inhibitor: <italic>E</italic>
<sub>int</sub> = <italic>E</italic>
<sub>vdW</sub> + <italic>E</italic>
<sub>ele</sub>.</p></fn><fn id="TF13"><p>
<sup>e</sup>
<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup> is the experimental half-maximal inhibitory concentration of the HLCIC obtained from reference<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref>, p<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup> = &#x02212;log<sub>10</sub>(<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0005" orientation="portrait" position="float"><label>Table 5.</label><caption><p>Regression analysis of computed interaction energies <italic>E</italic>
<sub>int</sub> and observed activities p<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup> of hybrid lactone&#x02013;chalcone and isatin&#x02013;chalcone HLCIC.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Statistical data of linear regression</th><th align="center">(C)</th></tr></thead><tbody valign="top"><tr><td align="left"><inline-formula id="ilm0003"><alternatives><inline-graphic xlink:href="IENZ_A_1564288_ILM0003.gif"/><mml:math id="ID0EAABBHAAARBBBA"><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi>I</mml:mi><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:msup><mml:mrow/><mml:mrow><mml:mo>&#x02009;</mml:mo><mml:mtext>exp</mml:mtext><mml:mo>&#x02009;</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>0.0548</mml:mn><mml:mo>&#x000b7;</mml:mo><mml:mo>&#x00394;</mml:mo><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mtext>int</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>5.1734</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> (C)</td><td align="center">&#x000a0;</td></tr><tr><td align="left">Number of compounds, n</td><td align="center">15</td></tr><tr><td align="left">Squared correlation coefficient of regression, <italic>R</italic><sup>2</sup></td><td align="center">0.85</td></tr><tr><td align="left">LOO cross-validated correlation coefficient, <italic>R</italic><sub>xv</sub><sup>2</sup></td><td align="center">0.83</td></tr><tr><td align="left">Standard error of regression, &#x003c3;</td><td align="center">0.106</td></tr><tr><td align="left">Statistical significance of regression, Fischer <italic>F</italic>-test</td><td align="center">72.10</td></tr><tr><td align="left">Level of statistical significance, &#x003b1;</td><td align="center">&#x0003e;95%</td></tr><tr><td align="left">Range of activities <italic>IC</italic><sub>50</sub><sup>exp</sup> (&#x003bc;M)</td><td align="center">6.8&#x02013;90.0</td></tr></tbody></table></table-wrap><p>The prominent role of the van der Waals (vdW) component of <italic>E</italic>
<sub>int</sub> in the binding affinity of HLCIC to FP-2 of <italic>Pf</italic> is highlighted by the correlation between individual contributions to the overall <italic>E</italic>
<sub>int</sub>. In addition, to assess the impact of the residues occupying individual active site pockets (S1, S2, S3, and S1&#x02019;; <xref ref-type="fig" rid="F0004">Figure 4</xref>) we have analyzed their contribution to the overall <italic>E</italic>
<sub>int</sub> (<xref rid="t0006" ref-type="table">Table 6</xref>; <xref ref-type="fig" rid="F0006">Figure 6</xref>). The contribution of all the four pockets together explained 88% of the FP-2 inhibitory potencies of the training set inhibitors. This fell down to 31% when removing the contribution of the S2 pocket (67%). The filling of the S2 pocket by function groups of the inhibitors is therefore crucial for the FP-2:HLCIC1-15 affinity. Thus, our virtual FP-2 inhibitor design prioritised optimal filling of the S2 pocket by the HLCIC analogues.</p><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>Plot of the correlation between interaction energies of residues belonging to individual active site pockets (S1, S2, S3, and S&#x02019;1) and observed activities p<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1564288_F0006_B"/></fig><table-wrap id="t0006" orientation="portrait" position="float"><label>Table 6.</label><caption><p>Active site residue contribution to <italic>E</italic>
<sub>int</sub> in FP-2:HLCIC1 complex (kcal&#x000b7;mol<sup>&#x02212;1</sup>).</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Pockets<hr/></th><th rowspan="2" align="center">pIC<sub>50</sub><sup>exp</sup></th><th colspan="7" align="center">S1<hr/></th><th colspan="7" align="center">S2<hr/></th></tr><tr><th align="left">Residue</th><th align="center">GLN 36</th><th align="center">GLY 40</th><th align="center">SER 41</th><th align="center">CYS 42</th><th align="center">CYS 80</th><th align="center">ASN 81</th><th align="center">Total</th><th align="center">LEU 84</th><th align="center">ILE 85</th><th align="center">SER 149</th><th align="center">LEU 172</th><th align="center">ALA 175</th><th align="center">ASP-234</th><th align="center">Total</th></tr></thead><tbody valign="top"><tr><td align="left">HLCIC 1</td><td align="char" char=".">5.17</td><td align="char" char=".">&#x02212;1.5</td><td align="char" char=".">&#x02212;3.1</td><td align="char" char=".">&#x02212;0.7</td><td align="char" char=".">0.5</td><td align="char" char=".">&#x02212;1.2</td><td align="char" char=".">&#x02212;3.8</td><td align="char" char=".">&#x02212;9.9</td><td align="char" char=".">&#x02212;3.7</td><td align="char" char=".">&#x02212;1.6</td><td align="char" char=".">&#x02212;1.9</td><td align="char" char=".">&#x02212;4.0</td><td align="char" char=".">&#x02212;2.3</td><td align="char" char=".">&#x02212;2.5</td><td align="char" char=".">&#x02212;16.0</td></tr><tr><td align="left">HLCIC 2</td><td align="char" char=".">4.99</td><td align="char" char=".">&#x02212;0.9</td><td align="char" char=".">&#x02212;2.9</td><td align="char" char=".">&#x02212;2.9</td><td align="char" char=".">0.5</td><td align="char" char=".">&#x02212;1.0</td><td align="char" char=".">&#x02212;3.8</td><td align="char" char=".">&#x02212;11.1</td><td align="char" char=".">&#x02212;3.7</td><td align="char" char=".">&#x02212;1.6</td><td align="char" char=".">&#x02212;1.9</td><td align="char" char=".">&#x02212;4.0</td><td align="char" char=".">&#x02212;2.3</td><td align="char" char=".">&#x02212;2.6</td><td align="char" char=".">&#x02212;16.1</td></tr><tr><td align="left">HLCIC 3</td><td align="char" char=".">4.94</td><td align="char" char=".">&#x02212;1.9</td><td align="char" char=".">&#x02212;3.2</td><td align="char" char=".">&#x02212;0.9</td><td align="char" char=".">&#x02212;0.7</td><td align="char" char=".">&#x02212;1.1</td><td align="char" char=".">&#x02212;2.5</td><td align="char" char=".">&#x02212;10.4</td><td align="char" char=".">&#x02212;3.7</td><td align="char" char=".">&#x02212;2.1</td><td align="char" char=".">&#x02212;1.6</td><td align="char" char=".">&#x02212;3.5</td><td align="char" char=".">&#x02212;2.4</td><td align="char" char=".">&#x02212;0.3</td><td align="char" char=".">&#x02212;13.5</td></tr><tr><td align="left">HLCIC 4</td><td align="char" char=".">4.59</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">&#x02212;0.8</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">1.1</td><td align="char" char=".">&#x02212;0.3</td><td align="char" char=".">&#x02212;3.4</td><td align="char" char=".">&#x02212;4.1</td><td align="char" char=".">&#x02212;4.1</td><td align="char" char=".">&#x02212;1.4</td><td align="char" char=".">&#x02212;1.5</td><td align="char" char=".">&#x02212;2.7</td><td align="char" char=".">&#x02212;2.2</td><td align="char" char=".">&#x02212;2.0</td><td align="char" char=".">&#x02212;13.9</td></tr><tr><td align="left">HLCIC 5</td><td align="char" char=".">4.81</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">&#x02212;0.9</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">1.1</td><td align="char" char=".">&#x02212;0.3</td><td align="char" char=".">&#x02212;3.5</td><td align="char" char=".">&#x02212;4.5</td><td align="char" char=".">&#x02212;4.1</td><td align="char" char=".">&#x02212;1.4</td><td align="char" char=".">&#x02212;1.5</td><td align="char" char=".">&#x02212;2.8</td><td align="char" char=".">&#x02212;2.2</td><td align="char" char=".">&#x02212;1.9</td><td align="char" char=".">&#x02212;13.9</td></tr><tr><td align="left">HLCIC 6</td><td align="char" char=".">4.04</td><td align="char" char=".">&#x02212;3.1</td><td align="char" char=".">&#x02212;3.2</td><td align="char" char=".">&#x02212;2.0</td><td align="char" char=".">&#x02212;2.6</td><td align="char" char=".">&#x02212;1.6</td><td align="char" char=".">&#x02212;5.6</td><td align="char" char=".">&#x02212;18.2</td><td align="char" char=".">&#x02212;0.2</td><td align="char" char=".">&#x02212;0.1</td><td align="char" char=".">&#x02212;0.1</td><td align="char" char=".">&#x02212;0.2</td><td align="char" char=".">&#x02212;0.7</td><td align="char" char=".">&#x02212;0.1</td><td align="char" char=".">&#x02212;1.3</td></tr><tr><td align="left">HLCIC 7</td><td align="char" char=".">4.96</td><td align="char" char=".">&#x02212;1.4</td><td align="char" char=".">&#x02212;2.5</td><td align="char" char=".">&#x02212;0.7</td><td align="char" char=".">0.4</td><td align="char" char=".">&#x02212;1.0</td><td align="char" char=".">&#x02212;3.9</td><td align="char" char=".">&#x02212;9.1</td><td align="char" char=".">&#x02212;3.7</td><td align="char" char=".">&#x02212;2.0</td><td align="char" char=".">&#x02212;1.8</td><td align="char" char=".">&#x02212;3.7</td><td align="char" char=".">&#x02212;2.2</td><td align="char" char=".">&#x02212;1.2</td><td align="char" char=".">&#x02212;14.7</td></tr><tr><td align="left">HLCIC 8</td><td align="char" char=".">4.55</td><td align="char" char=".">&#x02212;0.8</td><td align="char" char=".">&#x02212;2.0</td><td align="char" char=".">&#x02212;0.7</td><td align="char" char=".">&#x02212;0.8</td><td align="char" char=".">&#x02212;0.9</td><td align="char" char=".">&#x02212;4.4</td><td align="char" char=".">&#x02212;9.6</td><td align="char" char=".">&#x02212;2.7</td><td align="char" char=".">&#x02212;1.6</td><td align="char" char=".">&#x02212;0.6</td><td align="char" char=".">&#x02212;0.3</td><td align="char" char=".">&#x02212;1.7</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;6.8</td></tr><tr><td align="left">HLCIC 9</td><td align="char" char=".">4.80</td><td align="char" char=".">&#x02212;1.3</td><td align="char" char=".">&#x02212;2.7</td><td align="char" char=".">&#x02212;1.1</td><td align="char" char=".">0.8</td><td align="char" char=".">&#x02212;1.2</td><td align="char" char=".">&#x02212;4.0</td><td align="char" char=".">&#x02212;9.5</td><td align="char" char=".">&#x02212;3.7</td><td align="char" char=".">&#x02212;1.5</td><td align="char" char=".">&#x02212;1.6</td><td align="char" char=".">&#x02212;3.5</td><td align="char" char=".">&#x02212;1.7</td><td align="char" char=".">&#x02212;1.0</td><td align="char" char=".">&#x02212;13.1</td></tr><tr><td align="left">HLCIC 10</td><td align="char" char=".">4.80</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">&#x02212;1.3</td><td align="char" char=".">&#x02212;1.1</td><td align="char" char=".">0.4</td><td align="char" char=".">&#x02212;0.7</td><td align="char" char=".">&#x02212;5.2</td><td align="char" char=".">&#x02212;8.4</td><td align="char" char=".">&#x02212;2.5</td><td align="char" char=".">&#x02212;0.6</td><td align="char" char=".">&#x02212;1.0</td><td align="char" char=".">&#x02212;2.2</td><td align="char" char=".">&#x02212;1.4</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">&#x02212;8.2</td></tr><tr><td align="left">HLCIC 11</td><td align="char" char=".">4.82</td><td align="char" char=".">&#x02212;0.3</td><td align="char" char=".">&#x02212;1.2</td><td align="char" char=".">&#x02212;0.9</td><td align="char" char=".">&#x02212;0.7</td><td align="char" char=".">&#x02212;0.7</td><td align="char" char=".">&#x02212;5.2</td><td align="char" char=".">&#x02212;9.0</td><td align="char" char=".">&#x02212;2.6</td><td align="char" char=".">&#x02212;0.7</td><td align="char" char=".">&#x02212;0.9</td><td align="char" char=".">&#x02212;2.4</td><td align="char" char=".">&#x02212;1.5</td><td align="char" char=".">&#x02212;0.6</td><td align="char" char=".">&#x02212;8.8</td></tr><tr><td align="left">HLCIC 12</td><td align="char" char=".">4.81</td><td align="char" char=".">&#x02212;2.1</td><td align="char" char=".">&#x02212;3.9</td><td align="char" char=".">&#x02212;1.3</td><td align="char" char=".">&#x02212;0.7</td><td align="char" char=".">&#x02212;1.2</td><td align="char" char=".">&#x02212;3.0</td><td align="char" char=".">&#x02212;12.2</td><td align="char" char=".">&#x02212;3.3</td><td align="char" char=".">&#x02212;1.0</td><td align="char" char=".">&#x02212;0.9</td><td align="char" char=".">&#x02212;3.2</td><td align="char" char=".">&#x02212;1.5</td><td align="char" char=".">&#x02212;0.1</td><td align="char" char=".">&#x02212;9.9</td></tr><tr><td align="left">HLCIC 13</td><td align="char" char=".">5.00</td><td align="char" char=".">&#x02212;0.7</td><td align="char" char=".">&#x02212;1.8</td><td align="char" char=".">&#x02212;0.8</td><td align="char" char=".">0.1</td><td align="char" char=".">&#x02212;1.0</td><td align="char" char=".">&#x02212;5.8</td><td align="char" char=".">&#x02212;10.1</td><td align="char" char=".">&#x02212;3.7</td><td align="char" char=".">&#x02212;1.7</td><td align="char" char=".">&#x02212;2.1</td><td align="char" char=".">&#x02212;3.7</td><td align="char" char=".">&#x02212;1.7</td><td align="char" char=".">&#x02212;2.7</td><td align="char" char=".">&#x02212;15.7</td></tr><tr><td align="left">HLCIC 14</td><td align="char" char=".">4.97</td><td align="char" char=".">&#x02212;1.2</td><td align="char" char=".">&#x02212;3.1</td><td align="char" char=".">&#x02212;1.0</td><td align="char" char=".">0.1</td><td align="char" char=".">&#x02212;1.1</td><td align="char" char=".">&#x02212;5.1</td><td align="char" char=".">&#x02212;11.4</td><td align="char" char=".">&#x02212;3.7</td><td align="char" char=".">&#x02212;1.6</td><td align="char" char=".">&#x02212;2.0</td><td align="char" char=".">&#x02212;3.6</td><td align="char" char=".">&#x02212;1.8</td><td align="char" char=".">&#x02212;2.2</td><td align="char" char=".">&#x02212;14.9</td></tr><tr><td align="left">HLCIC 15<hr/></td><td align="char" char=".">4.78<hr/></td><td align="char" char=".">&#x02212;0.9<hr/></td><td align="char" char=".">&#x02212;2.0<hr/></td><td align="char" char=".">&#x02212;0.6<hr/></td><td align="char" char=".">1.6<hr/></td><td align="char" char=".">&#x02212;0.9<hr/></td><td align="char" char=".">&#x02212;3.9<hr/></td><td align="char" char=".">&#x02212;6.6<hr/></td><td align="char" char=".">&#x02212;3.8<hr/></td><td align="char" char=".">&#x02212;1.6<hr/></td><td align="char" char=".">&#x02212;2.2<hr/></td><td align="char" char=".">&#x02212;3.9<hr/></td><td align="char" char=".">&#x02212;1.9<hr/></td><td align="char" char=".">&#x02212;2.7<hr/></td><td align="char" char=".">&#x02212;16.1<hr/></td></tr><tr><td align="left">Pockets<hr/></td><td align="center">&#x000a0;</td><td colspan="6" align="center">S3<hr/></td><td colspan="8" align="center">S1&#x02019;<hr/></td></tr><tr><td align="left">Residue<hr/></td><td align="center">pIC<sub>50</sub><sup>exp</sup><hr/></td><td align="center">LYS + 76<hr/></td><td align="center">ASN 77<hr/></td><td align="center">TYR 78<hr/></td><td align="center">GLY 82<hr/></td><td align="center">GLY 83<hr/></td><td align="center">Total<hr/></td><td align="center">VAL150<hr/></td><td align="center">VAL 152<hr/></td><td align="center">ALA 157<hr/></td><td align="center">ASN 173<hr/></td><td align="center">HISD174<hr/></td><td align="center">TRP 206<hr/></td><td align="center">ASN 204<hr/></td><td align="center">Total<hr/></td></tr><tr><td align="left">HLCIC 1</td><td align="char" char=".">5.17</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">&#x02212;8.3</td><td align="char" char=".">&#x02212;3.0</td><td align="char" char=".">&#x02212;3.8</td><td align="char" char=".">&#x02212;15.9</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">0.0</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;3.0</td><td align="char" char=".">&#x02212;4.6</td><td align="char" char=".">&#x02212;2.4</td><td align="char" char=".">&#x02212;0.1</td><td align="char" char=".">&#x02212;10.7</td></tr><tr><td align="left">HLCIC 2</td><td align="char" char=".">4.99</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">&#x02212;8.3</td><td align="char" char=".">&#x02212;2.9</td><td align="char" char=".">&#x02212;3.8</td><td align="char" char=".">&#x02212;15.8</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">&#x02212;0.2</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;3.0</td><td align="char" char=".">&#x02212;4.2</td><td align="char" char=".">&#x02212;1.5</td><td align="char" char=".">&#x02212;0.1</td><td align="char" char=".">&#x02212;9.5</td></tr><tr><td align="left">HLCIC 3</td><td align="char" char=".">4.94</td><td align="char" char=".">&#x02212;0.3</td><td align="char" char=".">&#x02212;0.3</td><td align="char" char=".">&#x02212;6.2</td><td align="char" char=".">&#x02212;2.3</td><td align="char" char=".">&#x02212;3.4</td><td align="char" char=".">&#x02212;12.6</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">0.0</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;3.6</td><td align="char" char=".">&#x02212;4.9</td><td align="char" char=".">&#x02212;1.7</td><td align="char" char=".">&#x02212;0.1</td><td align="char" char=".">&#x02212;10.8</td></tr><tr><td align="left">HLCIC 4</td><td align="char" char=".">4.59</td><td align="char" char=".">&#x02212;0.3</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">&#x02212;7.1</td><td align="char" char=".">&#x02212;3.3</td><td align="char" char=".">&#x02212;4.0</td><td align="char" char=".">&#x02212;15.2</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">0.0</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;4.1</td><td align="char" char=".">&#x02212;4.3</td><td align="char" char=".">&#x02212;0.2</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;9.2</td></tr><tr><td align="left">HLCIC 5</td><td align="char" char=".">4.81</td><td align="char" char=".">&#x02212;0.3</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">&#x02212;7.2</td><td align="char" char=".">&#x02212;3.3</td><td align="char" char=".">&#x02212;4.0</td><td align="char" char=".">&#x02212;15.2</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">0.0</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;4.4</td><td align="char" char=".">&#x02212;4.8</td><td align="char" char=".">&#x02212;0.3</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;10.1</td></tr><tr><td align="left">HLCIC 6</td><td align="char" char=".">4.04</td><td align="char" char=".">0.1</td><td align="char" char=".">&#x02212;0.1</td><td align="char" char=".">&#x02212;0.3</td><td align="char" char=".">&#x02212;2.0</td><td align="char" char=".">&#x02212;0.7</td><td align="char" char=".">&#x02212;3.0</td><td align="char" char=".">&#x02212;0.1</td><td align="char" char=".">0.0</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;4.2</td><td align="char" char=".">&#x02212;1.1</td><td align="char" char=".">&#x02212;2.4</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;7.8</td></tr><tr><td align="left">HLCIC 7</td><td align="char" char=".">4.96</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">&#x02212;8.5</td><td align="char" char=".">&#x02212;2.8</td><td align="char" char=".">&#x02212;4.1</td><td align="char" char=".">&#x02212;16.3</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">0.0</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;2.7</td><td align="char" char=".">&#x02212;4.5</td><td align="char" char=".">&#x02212;0.6</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;8.3</td></tr><tr><td align="left">HLCIC 8</td><td align="char" char=".">4.55</td><td align="char" char=".">&#x02212;0.8</td><td align="char" char=".">&#x02212;3.2</td><td align="char" char=".">&#x02212;2.9</td><td align="char" char=".">&#x02212;4.6</td><td align="char" char=".">&#x02212;4.2</td><td align="char" char=".">&#x02212;15.5</td><td align="char" char=".">&#x02212;0.2</td><td align="char" char=".">0.0</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;2.1</td><td align="char" char=".">&#x02212;5.2</td><td align="char" char=".">&#x02212;0.7</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;8.3</td></tr><tr><td align="left">HLCIC 9</td><td align="char" char=".">4.80</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">&#x02212;8.2</td><td align="char" char=".">&#x02212;3.0</td><td align="char" char=".">&#x02212;3.8</td><td align="char" char=".">&#x02212;15.9</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">0.0</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;2.7</td><td align="char" char=".">&#x02212;3.0</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;6.4</td></tr><tr><td align="left">HLCIC 10</td><td align="char" char=".">4.80</td><td align="char" char=".">&#x02212;0.9</td><td align="char" char=".">&#x02212;0.8</td><td align="char" char=".">&#x02212;8.3</td><td align="char" char=".">&#x02212;5.7</td><td align="char" char=".">&#x02212;5.3</td><td align="char" char=".">&#x02212;21.0</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">0.0</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;3.4</td><td align="char" char=".">&#x02212;1.7</td><td align="char" char=".">&#x02212;0.1</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;5.7</td></tr><tr><td align="left">HLCIC 11</td><td align="char" char=".">4.82</td><td align="char" char=".">&#x02212;0.9</td><td align="char" char=".">&#x02212;0.8</td><td align="char" char=".">&#x02212;8.3</td><td align="char" char=".">&#x02212;6.1</td><td align="char" char=".">&#x02212;5.4</td><td align="char" char=".">&#x02212;21.5</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">0.0</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;3.8</td><td align="char" char=".">&#x02212;1.9</td><td align="char" char=".">&#x02212;0.1</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;6.3</td></tr><tr><td align="left">HLCIC 12</td><td align="char" char=".">4.81</td><td align="char" char=".">&#x02212;0.2</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">&#x02212;5.5</td><td align="char" char=".">&#x02212;3.9</td><td align="char" char=".">&#x02212;4.8</td><td align="char" char=".">&#x02212;14.8</td><td align="char" char=".">&#x02212;0.3</td><td align="char" char=".">0.0</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;2.9</td><td align="char" char=".">&#x02212;3.4</td><td align="char" char=".">&#x02212;0.6</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;7.3</td></tr><tr><td align="left">HLCIC 13</td><td align="char" char=".">5.00</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">&#x02212;8.3</td><td align="char" char=".">&#x02212;3.0</td><td align="char" char=".">&#x02212;3.9</td><td align="char" char=".">&#x02212;16.1</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">0.0</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;2.6</td><td align="char" char=".">&#x02212;2.0</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;5.5</td></tr><tr><td align="left">HLCIC 14</td><td align="char" char=".">4.97</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">&#x02212;8.3</td><td align="char" char=".">&#x02212;3.2</td><td align="char" char=".">&#x02212;4.1</td><td align="char" char=".">&#x02212;16.4</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">0.0</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;2.7</td><td align="char" char=".">&#x02212;2.5</td><td align="char" char=".">&#x02212;1.4</td><td align="char" char=".">0.0</td><td align="char" char=".">&#x02212;7.0</td></tr><tr><td align="left">HLCIC 15</td><td align="char" char=".">4.78</td><td align="char" char=".">&#x02212;0.4</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">&#x02212;8.3</td><td align="char" char=".">&#x02212;3.1</td><td align="char" char=".">&#x02212;3.9</td><td align="char" char=".">&#x02212;16.1</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">&#x02212;0.1</td><td align="char" char=".">&#x02212;0.2</td><td align="char" char=".">&#x02212;4.2</td><td align="char" char=".">&#x02212;3.2</td><td align="char" char=".">&#x02212;0.5</td><td align="char" char=".">&#x02212;0.1</td><td align="char" char=".">&#x02212;8.9</td></tr></tbody></table></table-wrap><p>The PH4 pharmacophore model of FP-2 inhibition elaborated from QSAR model and training set of HLCIC<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref> is presented in <xref rid="t0007" ref-type="table">Tables 7</xref> and <xref rid="t0008" ref-type="table">8</xref> and <xref ref-type="fig" rid="F0007">Figure 7</xref>. The 3D-QSAR PH4 generation was carried out in three steps: constructive, subtractive, and optimisation step (<xref ref-type="sec" rid="s0002">Section 2</xref>). During the constructive phase of HypoGen the most active HLCIC, for which <italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>&#x02009;&#x02264;&#x02009;2&#x02009;&#x000d7;&#x02009;6.8&#x02009;&#x000b5;M, was selected as the leads. Thus, HLCIC1-3,7,13,14 (<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>&#x02009;&#x02264;&#x02009;13.6&#x02009;&#x000b5;M) were used to generate the starting PH4 features and those matching these leads were retained. During the subsequent subtractive phase, features which were present in more than half of the inactive HLCIC were removed. The PH4 models which contained all features were retained. None of the training set compounds was found to be inactive (<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>&#x0003e; 6.8&#x02009;&#x000d7;&#x02009;10<sup>3.5</sup>&#x02009;=&#x02009;21503.4&#x02009;&#x000b5;M). During the final optimisation phase, the score of the PH4 hypotheses was improved. Hypotheses were scored via simulated annealing protocol according to errors in the activity estimates from the regression and complexity. At the end of optimisation, 10 best scoring unique hypotheses (<xref rid="t0007" ref-type="table">Table 7</xref>) displaying five features were kept. The reliability of the generated PH4 models was then assessed using the calculated cost parameters ranging from 74.8 (Hypo1) to 94.7 (Hypo10). Their statistical data (costs, root-mean-square deviation 2.056&#x02009;&#x02264;&#x02009;<italic>RMSD</italic>&#x02009;&#x02264;&#x02009;2.777 and 0.89&#x02009;&#x02264;&#x02009;<italic>R</italic>
<sup>2</sup> &#x02264; 0.94) are listed in <xref rid="t0007" ref-type="table">Table 7</xref>. The PH4 Hypo1, with the best <italic>RMSD</italic> and highest <italic>R</italic>
<sup>2</sup> was retained for screening. Its regression equation p<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>&#x02009;=&#x02009;0.9958&#x000b7;p<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> + 0.0192 (<xref ref-type="fig" rid="F0007">Figure 7</xref>; <xref rid="t0008" ref-type="table">Table 8</xref>), both <italic>R</italic>
<sup>2</sup> and <italic>R</italic>
<sub>xv</sub>
<sup>2</sup> greater than 0.9 and <italic>F</italic>-test of 111.25 attest the predictive capacity of the PH4. The fixed cost of Hypo1 (74.8), lower than the null cost (296.7) by &#x00394;&#x02009;=&#x02009;221.9, is a chief indicator of the PH4 model predictability (&#x00394;&#x02009;&#x0003e;&#x02009;70 corresponds to a probability higher than 90% that the model represents a valid correlation<xref rid="CIT0022" ref-type="bibr">
<sup>22</sup>
</xref>). The difference &#x00394;&#x02009;&#x02265;&#x02009;202 for the set of 10 hypotheses confirms the high quality of the PH4 model. The best-selected hypothesis Hypo1 represents a PH4 model with a similar level of predictive power as the QSAR model utilising the GFE of E:I complex formation with a probability of 98%.</p><fig id="F0007" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>Distances (a), angles (b), features (c), and mapping (d) of the pharmacophore of the <italic>Pf</italic> FP-2 inhibition with the best training set inhibitor HLCIC1 (yellow)<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref>. The correlation plot of experimental vs. predicted inhibitory activity (e) is displayed. The features are coloured blue for hydrophobic aliphatic (HYd), green for hydrogen-bond (HB) acceptor (HBA), purple for HB donor (HBD) and orange for Aromatic (Ar). The arrows represent the projection of donor and acceptor features.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1564288_F0007_C"/></fig><table-wrap id="t0007" orientation="portrait" position="float"><label>Table 7.</label><caption><p>Output parameters of 10 generated PH4 hypotheses for test set HLCIC FP-2 inhibitors<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref> after CatScramble validation procedure.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Hypothesis</th><th align="center"><italic>RMSD</italic><xref ref-type="table-fn" rid="TF14">
<sup>a</sup>
</xref></th><th align="center"><italic>R</italic><sup>2</sup><xref ref-type="table-fn" rid="TF15">
<sup>b</sup>
</xref></th><th align="center">Total cost<xref ref-type="table-fn" rid="TF16">
<sup>c</sup>
</xref></th></tr></thead><tbody valign="top"><tr><td align="left">Hypo1</td><td align="char" char=".">2.056</td><td align="char" char=".">0.94</td><td align="char" char=".">74.8</td></tr><tr><td align="left">Hypo2</td><td align="char" char=".">2.368</td><td align="char" char=".">0.92</td><td align="char" char=".">80.7</td></tr><tr><td align="left">Hypo3</td><td align="char" char=".">2.463</td><td align="char" char=".">0.91</td><td align="char" char=".">83.5</td></tr><tr><td align="left">Hypo4</td><td align="char" char=".">2.3</td><td align="char" char=".">0.92</td><td align="char" char=".">84.5</td></tr><tr><td align="left">Hypo5</td><td align="char" char=".">2.574</td><td align="char" char=".">0.90</td><td align="char" char=".">86.3</td></tr><tr><td align="left">Hypo6</td><td align="char" char=".">2.614</td><td align="char" char=".">0.90</td><td align="char" char=".">88.4</td></tr><tr><td align="left">Hypo7</td><td align="char" char=".">2.624</td><td align="char" char=".">0.90</td><td align="char" char=".">89.6</td></tr><tr><td align="left">Hypo8</td><td align="char" char=".">2.738</td><td align="char" char=".">0.89</td><td align="char" char=".">91.8</td></tr><tr><td align="left">Hypo9</td><td align="char" char=".">2.682</td><td align="char" char=".">0.89</td><td align="char" char=".">92.1</td></tr><tr><td align="left">Hypo10</td><td align="char" char=".">2.777</td><td align="char" char=".">0.89</td><td align="char" char=".">94.7</td></tr><tr><td align="left">Fixed cost</td><td align="char" char=".">0</td><td align="char" char=".">1</td><td align="char" char=".">30.9</td></tr><tr><td align="left">Null cost</td><td align="char" char=".">6.142</td><td align="char" char=".">0</td><td align="char" char=".">296.7</td></tr></tbody></table><table-wrap-foot><fn id="TF14"><p>
<sup>a</sup>Root mean square deviation.</p></fn><fn id="TF15"><p>
<sup>b</sup>Squared correlation coefficient.</p></fn><fn id="TF16"><p>
<sup>c</sup>Overall cost parameter of the PH4.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0008" orientation="portrait" position="float"><label>Table 8.</label><caption><p>Regression analysis of p<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>
<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref> and computed p<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> of HLCIC towards the FP-2 of <italic>Pf</italic>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Statistical data of linear regression for Hypo 1 (D)</th><th align="center">&#x000a0;</th><th align="center">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td align="left"><inline-formula id="ilm0004"><alternatives><inline-graphic xlink:href="IENZ_A_1564288_ILM0004.gif"/><mml:math id="ID0EAABCHAAAKBBBA"><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi>I</mml:mi><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:msup><mml:mrow/><mml:mrow><mml:mtext>exp</mml:mtext><mml:mo>&#x02009;</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>0.9958</mml:mn><mml:mo>&#x000b7;</mml:mo><mml:mi mathvariant="normal">p</mml:mi><mml:mi>I</mml:mi><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:msup><mml:mrow/><mml:mrow><mml:mtext>pre</mml:mtext></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>0.0192</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> (D)</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr><tr><td align="left">Number of compounds, n</td><td align="center">15</td><td align="center">&#x000a0;</td></tr><tr><td align="left">Squared correlation coefficient of regression, <italic>R</italic><sup>2</sup></td><td align="center">0.89</td><td align="center">&#x000a0;</td></tr><tr><td align="left">LOO cross-validation squared correlation coefficient, <italic>R</italic><sub>xv</sub><sup>2</sup></td><td align="center">0.88</td><td align="center">&#x000a0;</td></tr><tr><td align="left">Standard error of regression, <italic>&#x003c3;</italic></td><td align="center">0.088</td><td align="center">&#x000a0;</td></tr><tr><td align="left">Statistical significance of regression, Fischer <italic>F</italic>-test</td><td align="center">111.249</td><td align="center">&#x000a0;</td></tr><tr><td align="left">Level of statistical significance, <italic>&#x003b1;</italic></td><td align="center">&#x0003e;95%</td><td align="center">&#x000a0;</td></tr><tr><td align="left">Range of activities <italic>IC</italic><sub>50</sub><sup>exp</sup> (&#x003bc;M)</td><td align="center">[6.8&#x02013;90]</td><td align="center">&#x000a0;</td></tr></tbody></table></table-wrap><p>The substantial predictive power of the generated PH4 model was also checked through the computed ratio of PH4-predicted and experimentally observed activities (p<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>/p<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>) for the VS, (<xref rid="t0001" ref-type="table">Table 1</xref>). The computed ratios are as follows: HLCIV1:1.006, HLCIV2:1.057, HLCIV3:0.97; all of them close to one.</p><p>We have built a VL of new HLCIC analogues compounds with a variety of substitutions in ortho, meta, and para positions of the benzene rings with the goal to identify more potent orally bioavailable inhibitors of the FP-2 of <italic>Pf</italic>.</p><p>During the VL enumeration, the <italic>R</italic>-groups listed in <xref rid="t0009" ref-type="table">Table 9</xref> were attached to positions <italic>R</italic>
<sub>1</sub>&#x02013;<italic>R</italic>
<sub>6</sub> of the HLCIC scaffold to form a virtual combinatorial library of the size: R1&#x02009;&#x000d7;&#x02009;R2 &#x000d7; R3 &#x000d7; R4 &#x000d7; R5 &#x000d7; R6&#x02009;=&#x02009;128&#x02009;&#x000d7;&#x02009;10&#x02009;&#x000d7;&#x02009;128&#x02009;&#x000d7;&#x02009;2 &#x000d7; 2&#x02009;&#x000d7;&#x02009;2&#x02009;=&#x02009;1,310,720 analogues for the scaffold SC1 (<xref rid="t0009" ref-type="table">Table 9</xref>) and R1 &#x000d7; R2 &#x000d7; R3 &#x000d7; R4 &#x000d7; R5 &#x000d7; R6&#x02009;=&#x02009;2&#x02009;&#x000d7;&#x02009;2&#x02009;&#x000d7;&#x02009;2&#x02009;&#x000d7;&#x02009;128&#x02009;&#x000d7;&#x02009;10&#x02009;&#x000d7;&#x02009;28&#x02009;=&#x02009;1,310,720 for SC2 (<xref rid="t0009" ref-type="table">Table 9</xref>) resulting together in 1,310,720&#x02009;&#x000d7;&#x02009;2&#x02009;=&#x02009;2,621,440 analogues. In order to match the substitution pattern of the best training set inhibitor HLCIC1 and taking into account the reported structural information about S pockets filling suitable for substitution<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref> not excluded through the Lipinski&#x02019;s rule violation (<italic>M<sub>w</sub></italic> &#x0003e; 500&#x02009;g/mol)<xref rid="CIT0041" ref-type="bibr">
<sup>41</sup>
</xref>, the VL underwent a focusing.</p><table-wrap id="t0009" orientation="portrait" position="float"><label>Table 9.</label><caption><p>
<italic>R</italic>-groups (fragments, building blocks, substituents) used in the design of the diversity VL of HLCIC analogues.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th colspan="2" align="center"><inline-graphic xlink:href="IENZ_A_1564288_ILG0004_B.gif" content-type="black-white"/><italic>R</italic><sub>1</sub>, <italic>R</italic><sub>2</sub>, <italic>R</italic><sub>3</sub>, <italic>R</italic><sub>4</sub>, <italic>R</italic><sub>5</sub> and <italic>R</italic><sub>6</sub>-groups <sup>a,b</sup><hr/></th><th colspan="2" align="center"><inline-graphic xlink:href="IENZ_A_1564288_ILG0005_B.gif" content-type="black-white"/>linker-isatin (-lki)<hr/></th></tr><tr><th colspan="4" align="left">R-group</th></tr></thead><tbody valign="top"><tr><td>1. &#x02013;F</td><td align="char" char=".">2. &#x02013;Cl</td><td align="char" char=".">3. &#x02013;Br</td><td align="char" char=".">4. &#x02013;I</td></tr><tr><td>5. &#x02013;OH</td><td align="char" char=".">6. &#x02013;SH</td><td align="char" char=".">7. &#x02013;NH<sub>2</sub></td><td align="char" char=".">8. &#x02013;OCH<sub>3</sub></td></tr><tr><td>9. &#x02013;OCl</td><td align="char" char=".">10. &#x02013;OBr</td><td align="char" char=".">11. &#x02013;OI</td><td align="char" char=".">12. &#x02013;OSH</td></tr><tr><td>13. &#x02013;OCH<sub>2</sub>OH</td><td align="char" char=".">14. &#x02013;OCH<sub>2</sub>Cl</td><td align="char" char=".">15. &#x02013;OCH<sub>2</sub>Br</td><td align="char" char=".">16. &#x02013;OCH<sub>2</sub>F</td></tr><tr><td>17. &#x02013;OCH<sub>2</sub>I</td><td align="char" char=".">18. &#x02013;OCH<sub>2</sub>SH</td><td align="char" char=".">19. &#x02013;OCH<sub>2</sub>NH<sub>2</sub></td><td align="char" char=".">20. &#x02013;OCH<sub>2</sub>COO&#x02013;</td></tr><tr><td>21. &#x02013;OCH<sub>2</sub>COOH</td><td align="char" char=".">22. &#x02013;OCH<sub>2</sub>CHO</td><td align="char" char=".">23. &#x02013;OCH<sub>2</sub>CN</td><td align="char" char=".">24. &#x02013;OCH<sub>2</sub>C(NH<sub>2</sub>)<sub>2</sub><sup>+</sup></td></tr><tr><td>25. &#x02013;OCH<sub>2</sub>CONH<sub>2</sub></td><td align="char" char=".">26. &#x02013;OCH<sub>2</sub>NO<sub>2</sub></td><td align="char" char=".">27. &#x02013;OCH<sub>2</sub>SO<sub>2</sub></td><td align="char" char=".">28. &#x02013;OCH<sub>2</sub>PO<sub>3</sub>H</td></tr><tr><td>29. &#x02013;(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub></td><td align="char" char=".">30. &#x02013;(CH<sub>2</sub>)<sub>3</sub>OH</td><td align="char" char=".">31. &#x02013;(CH<sub>2</sub>)<sub>3</sub>Cl</td><td align="char" char=".">32. &#x02013;(CH<sub>2</sub>)<sub>3</sub>Br</td></tr><tr><td>33. &#x02013;(CH<sub>2</sub>)<sub>3</sub>F</td><td align="char" char=".">34. &#x02013;(CH<sub>2</sub>)<sub>3</sub>I</td><td align="char" char=".">35. &#x02013;(CH<sub>2</sub>)<sub>3</sub>COO&#x02013;</td><td align="char" char=".">36. &#x02013;(CH<sub>2</sub>)<sub>3</sub>COOH</td></tr><tr><td>37. &#x02013;(CH<sub>2</sub>)<sub>3</sub>CHO</td><td align="char" char=".">38. &#x02013;(CH<sub>2</sub>)<sub>3</sub>CN</td><td align="char" char=".">39. &#x02013;(CH<sub>2</sub>)<sub>3</sub>C(NH<sub>2</sub>)<sub>2</sub><sup>+</sup></td><td align="char" char=".">40. &#x02013;(CH<sub>2</sub>)<sub>3</sub>CONH<sub>2</sub></td></tr><tr><td>41. &#x02013;(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>CO</td><td align="char" char=".">42. &#x02013;(CH<sub>2</sub>)<sub>3</sub>NO<sub>2</sub></td><td align="char" char=".">43. &#x02013;(CH<sub>2</sub>)<sub>3</sub>SO<sub>2</sub>H</td><td align="char" char=".">44. &#x02013;(CH<sub>2</sub>)<sub>3</sub>PO<sub>3</sub>H</td></tr><tr><td>45. cycloprop-2-enyl</td><td align="char" char=".">46. 2-hydroxycycloprop-2-en-1-yl</td><td align="char" char=".">47. 2,3-dihydroxycycloprop-2-enyl</td><td align="char" char=".">48. 2-amino-3-hydroxycycloprop-2-enyl</td></tr><tr><td>49. 2,3-diaminocycloprop-2-enyl</td><td align="char" char=".">50. 2-amino-3-fluorocycloprop-2-enyl</td><td align="char" char=".">51. 2,3-difluorocycloprop-2-enyl</td><td align="char" char=".">52. 2-chloro-3-fluorocycloprop-2-enyl</td></tr><tr><td>53. 2,3-dichlorocycloprop-2-enyl</td><td align="char" char=".">54. 2-chloro-3-mercaptocycloprop-2-enyl</td><td align="char" char=".">55. 2<italic>H</italic>-azirin-2-yl</td><td align="char" char=".">56. 3<italic>H</italic>-diazirin-3-yl</td></tr><tr><td>57. 2<italic>H</italic>-triazirin-2-yl</td><td align="char" char=".">58. 1<italic>H</italic>-tetrazol-5-yl</td><td align="char" char=".">59. 1,4-dioxan-2-yl</td><td align="char" char=".">60. &#x02013;COO&#x02013;</td></tr><tr><td>61. &#x02013;COOH</td><td align="char" char=".">62. &#x02013;CHO</td><td align="char" char=".">63. &#x02013;CN</td><td align="char" char=".">64. &#x02013;C(NH<sub>2</sub>)+</td></tr><tr><td>65. &#x02013;CONH<sub>2</sub><sup>+</sup></td><td align="char" char=".">66. &#x02013;NCH<sub>2</sub>O</td><td align="char" char=".">67. &#x02013;NO<sub>2</sub></td><td align="char" char=".">68. &#x02013;SO<sub>2</sub></td></tr><tr><td>69. &#x02013;PO<sub>3</sub>H</td><td align="char" char=".">70. &#x02013;C<sub>2</sub>SO<sub>2</sub>H</td><td align="char" char=".">80. &#x02013;HSO<sub>2</sub></td><td align="char" char=".">81. &#x02013;CF<sub>3</sub></td></tr><tr><td>82. &#x02013;CCl<sub>3</sub></td><td align="char" char=".">83. &#x02013;CH<sub>2</sub>CF<sub>3</sub></td><td align="char" char=".">84. &#x02013;CH<sub>2</sub>CCl<sub>3</sub></td><td align="char" char=".">85. &#x02013;(CH<sub>2</sub>)<sub>2</sub>CCl<sub>3</sub></td></tr><tr><td>86. &#x02013;(CH<sub>2</sub>)<sub>2</sub>CF<sub>3</sub></td><td align="char" char=".">87. &#x02013;(CH<sub>2</sub>)<sub>2</sub>F</td><td align="char" char=".">88. &#x02013;N&#x02009;=&#x02009;NH</td><td align="char" char=".">89. &#x02013;ON&#x02009;=&#x02009;NH</td></tr><tr><td>90. &#x02013;ON&#x02009;=&#x02009;NOH</td><td align="char" char=".">91. &#x02013;N&#x02009;=&#x02009;NOH</td><td align="char" char=".">92. &#x02013;NO</td><td align="char" char=".">93. &#x02013;CH&#x02009;=&#x02009;CH<sub>2</sub></td></tr><tr><td>94. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CH<sub>2</sub></td><td align="char" char=".">95. &#x02013;(CH<sub>2</sub>)4F</td><td align="char" char=".">96. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;C(NH<sub>2</sub>)<sub>2</sub></td><td align="char" char=".">97. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;C(OH)NH<sub>2</sub></td></tr><tr><td>98. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;C(OH)<sub>2</sub></td><td align="char" char=".">99. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CHOH</td><td align="char" char=".">100. &#x02013;(CH<sub>2</sub>)<sub>4</sub>OH</td><td align="char" char=".">101. &#x02013;(CH<sub>2</sub>)<sub>4</sub>NH<sub>2</sub></td></tr><tr><td>102. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CH&#x02013;CH<sub>2</sub>OH</td><td align="char" char=".">103. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CH&#x02013;CH<sub>2</sub>NH<sub>2</sub></td><td align="char" char=".">104. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CH&#x02013;CH<sub>2</sub>NCO</td><td align="char" char=".">105. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CH&#x02013;CH<sub>2</sub>NO<sub>2</sub></td></tr><tr><td>106. &#x02013;H<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CH&#x02013;CH<sub>2</sub>F</td><td align="char" char=".">107. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CH&#x02013;CH<sub>2</sub>COO&#x02013;</td><td align="char" char=".">108. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CH&#x02013;CH<sub>2</sub>COOH</td><td align="char" char=".">109. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CH&#x02013;CH<sub>2</sub>CO</td></tr><tr><td>110. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CH&#x02013;CH<sub>2</sub>CN</td><td align="char" char=".">111. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CH&#x02013;CH<sub>2</sub>C(NH<sub>2</sub>)<sub>2</sub><sup>+</sup></td><td align="char" char=".">112. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CH&#x02013;CH<sub>2</sub>CONH<sub>2</sub></td><td align="char" char=".">113. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CH&#x02013;CH<sub>2</sub>SO<sub>2</sub></td></tr><tr><td>114. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CH&#x02013;CH<sub>2</sub>&#x02013;PO<sub>3</sub></td><td align="char" char=".">115. &#x02013;CH&#x02009;=&#x02009;C(OH)<sub>2</sub></td><td align="char" char=".">116. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;C(NH<sub>2</sub>)NO<sub>2</sub><sup>2&#x02212;</sup></td><td align="char" char=".">117. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;C(NO<sub>2</sub><sup>2&#x02212;</sup>)<sub>2</sub></td></tr><tr><td>118. &#x02013;(CH<sub>2</sub>)<sub>4</sub>COOH</td><td align="char" char=".">119. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CH&#x02013;CH<sub>2</sub>&#x02013;NH&#x02013;CHO</td><td align="char" char=".">120. &#x02013;CH<sub>2</sub>&#x02013;CH&#x02009;=&#x02009;CH&#x02013;(CH<sub>2</sub>)<sub>2</sub>&#x02013;CN</td><td align="char" char=".">121. 3-(2,3-difluorocycloprop-2-enyl) propyl</td></tr><tr><td>122. 3,4-difluorofuran-2-yl</td><td align="char" char=".">123. &#x02013;(2-CN-6-MeO-1,2,5-triazin-4-yl)Me</td><td align="char" char=".">124. &#x02013;(2-cyano-pyrimidin-4-yl)Me</td><td align="char" char=".">125. 2-cyano-pyrimidin-4-yl</td></tr><tr><td>126. (pyrimidin-4-yl)Me</td><td align="char" char=".">127. pyrimidin-4-yl</td><td align="char" char=".">128. (tetrahydro-2<italic>H</italic>-pyran)Me</td><td align="char" char=".">129. (piperidin-4-yl)Me</td></tr><tr><td>130. (isopropyl-piperidin-4-yl)Me</td><td align="char" char=".">131. (tetrahydrofuran-2-yl) ethyl</td><td align="char" char=".">132. &#x02013;CH(Me)<sub>2</sub></td><td align="char" char=".">133. &#x02013;CH<sub>2</sub>&#x02013;CH(Me)&#x02013;CH<sub>3</sub></td></tr><tr><td>134. &#x02013;CH<sub>2</sub>&#x02013;CH(Me)&#x02013;(CH<sub>2</sub>)<sub>2</sub>OH</td><td align="char" char=".">135. &#x02013;CH<sub>2</sub>&#x02013;CH(Me)&#x02013;(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub></td><td align="char" char=".">136. &#x02013;CH<sub>2</sub>&#x02013;CH(Me)&#x02013;(CH<sub>2</sub>)<sub>2</sub>Cl</td><td align="char" char=".">137. &#x02013;CH(CH<sub>2</sub>)<sub>2</sub>&#x02013;CH<sub>3</sub> 138. &#x02013;lki</td></tr></tbody></table><table-wrap-foot><fn id="TF17"><p>
<sup>a</sup>Fragments 1&#x02013;128 were used in <italic>R</italic>
<sub>1</sub>-groups and <italic>R</italic>
<sub>3</sub>-groups; fragments 1&#x02013;10 were used in <italic>R</italic>
<sub>2</sub>-group, fragments 138 and H for <italic>R</italic>
<sub>4</sub>, R<sub>5</sub>, and <italic>R</italic>
<sub>6</sub> as scaffold SC1. Reversely fragments 1&#x02013;128 were used in <italic>R</italic>
<sub>6</sub>-groups and <italic>R</italic>
<sub>4</sub>-groups; fragments 1&#x02013;10 were used in <italic>R</italic>
<sub>5</sub>-group, fragments 138 and H for <italic>R</italic>
<sub>3</sub>, R<sub>2</sub>, and <italic>R</italic>
<sub>1</sub> as scaffold SC2. Fragments 129&#x02013;138 were used intuitively as <italic>R</italic>
<sub>6</sub>-groups substituents for the best VL hits at P2 position according to Schechter and Berger notation<xref rid="CIT0042" ref-type="bibr">
<sup>42</sup>
</xref>.</p></fn><fn id="TF18"><p>
<sup>b</sup>(&#x02013;) bond indicates the attachment points of individual fragments.</p></fn></table-wrap-foot></table-wrap><p>To increase the content of drug-like and orally bioavailable analogues, the initial VL was filtered in an ADME-based focusing step. Only those molecules that satisfied the Lipinski&#x02019;s rule of five<xref rid="CIT0041" ref-type="bibr">
<sup>41</sup>
</xref> computed using QikProp<xref rid="CIT0016" ref-type="bibr">
<sup>16</sup>
</xref>, were kept.</p><p>From the initial set of 2,621,440 (1,310,720&#x02009;&#x000d7;&#x02009;2) analogues, 18,288 (9144&#x02009;&#x000d7;&#x02009;2) fulfilled the Lipinski test (except the restriction <italic>M<sub>w</sub></italic> &#x0003c; 500&#x02009;g/mol). Out of them, 141 analogues mapped to the 5 feature PH4 pharmacophore. The 81 best fitting analogues (PH4 hits) were retained and submitted to structure-based screening using the QSAR model and computed GFE of the FP-2:HLCIC complex formation. The calculated &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> of the FP-2:HLCIC complexes of the hits, their components as well as predicted half-maximal inhibitory concentrations <italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> estimated from the correlation equation (B) (<xref rid="t0003" ref-type="table">Table 3</xref>) are listed in <xref rid="t0010" ref-type="table">Table 10</xref>. Thirty-three others HLClC new analogues were added from an intuitive substitution approach intended to fill better the enzyme S2 pocket; they are listed in <xref rid="t0011" ref-type="table">Table 11</xref>. In the majority of new HLCIC analogues, the estimated inhibitory potencies are better than that for the most active training set inhibitor HLCIC1 (<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>&#x02009;=&#x02009;6.8&#x02009;&#x000b5;M)<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref>.</p><table-wrap id="t0010" orientation="portrait" position="float"><label>Table 10.</label><caption><p>GFE of FP-2:HLCIC complex formation and its components for the 81 virtually designed HLCIC exploring the pockets S1, S1&#x02019;, and S3.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><tbody valign="top"><tr><td colspan="7"><inline-graphic xlink:href="IENZ_A_1564288_ILG0006_B.gif" content-type="black-white"/><hr/></td></tr><tr><td rowspan="2" align="left">No</td><td align="left">Analogues</td><td align="center">&#x00394;&#x00394;<italic>H</italic><sub>MM</sub><xref ref-type="table-fn" rid="TF19">
<sup>a</sup>
</xref></td><td align="center">&#x00394;&#x00394;<italic>G</italic><sub>sol</sub><xref ref-type="table-fn" rid="TF20">
<sup>b</sup>
</xref></td><td align="center">&#x00394;&#x00394;<italic>TS</italic><sub>vib</sub><xref ref-type="table-fn" rid="TF21">
<sup>c</sup>
</xref></td><td align="center">&#x00394;&#x00394;<italic>G</italic><sub>com</sub><xref ref-type="table-fn" rid="TF22">
<sup>d</sup>
</xref></td><td align="center"><italic>IC</italic><sub>50</sub><sup>pre</sup><xref ref-type="table-fn" rid="TF23">
<sup>e</sup>
</xref></td></tr><tr><td align="left">HLCIC1</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">6800<xref ref-type="table-fn" rid="TF24">
<sup>f</sup>
</xref></td></tr><tr><td>&#x000a0;</td><td colspan="6">Ortho 1 (o.SC1)</td></tr><tr><td colspan="7" align="left">&#x000a0;<hr/></td></tr><tr><td align="left">1</td><td align="left">33&#x02013;5&#x02013;4&#x02013;lki&#x02013;H&#x02013;H</td><td align="char" char=".">15.57</td><td align="char" char=".">&#x02212;1.88</td><td align="char" char=".">1.08</td><td align="char" char=".">12.59</td><td align="char" char=".">16410</td></tr><tr><td align="left">2</td><td align="left">31&#x02013;2&#x02013;30&#x02013;lki&#x02013;H&#x02013;H</td><td align="char" char=".">10.97</td><td align="char" char=".">&#x02212;1.13</td><td align="char" char=".">&#x02212;0.53</td><td align="char" char=".">10.38</td><td align="char" char=".">14550</td></tr><tr><td align="left">3</td><td align="left">31&#x02013;H&#x02013;100&#x02013;lki&#x02013;H&#x02013;H</td><td align="char" char=".">10.46</td><td align="char" char=".">&#x02212;2.53</td><td align="char" char=".">4.47</td><td align="char" char=".">3.44</td><td align="char" char=".">9980</td></tr><tr><td align="left">4</td><td align="left">30&#x02013;6&#x02013;1&#x02013;lki&#x02013;H&#x02013;H</td><td align="char" char=".">12.32</td><td align="char" char=".">&#x02212;1.22</td><td align="char" char=".">0.34</td><td align="char" char=".">10.76</td><td align="char" char=".">14850</td></tr><tr><td align="left">5</td><td align="left">34&#x02013;6&#x02013;102&#x02013;lki&#x02013;H&#x02013;H</td><td align="char" char=".">9.70</td><td align="char" char=".">&#x02212;1.11</td><td align="char" char=".">3.78</td><td align="char" char=".">4.80</td><td align="char" char=".">10740</td></tr><tr><td colspan="7" align="left">&#x000a0;<hr/></td></tr><tr><td align="left">No</td><td align="left">Meta 1 (m.SC1)</td><td align="left">&#x00394;&#x00394;<italic>H</italic><sub>MM</sub></td><td align="left">&#x00394;&#x00394;<italic>G</italic><sub>sol</sub></td><td align="left">&#x00394;&#x00394;<italic>TS</italic><sub>vib</sub></td><td align="left">&#x00394;&#x00394;<italic>G</italic><sub>com</sub></td><td align="left"><italic>IC</italic><sub>50</sub><sup>pre</sup></td></tr><tr><td colspan="7" align="left">&#x000a0;<hr/></td></tr><tr><td align="left">6</td><td align="left">51&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;67.28</td><td align="char" char=".">1.49</td><td align="char" char=".">&#x02212;11.50</td><td align="char" char=".">&#x02212;54.29</td><td align="char" char=".">430</td></tr><tr><td align="left">7</td><td align="left">2&#x02013;8&#x02013;83&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;47.00</td><td align="char" char=".">0.08</td><td align="char" char=".">&#x02212;4.35</td><td align="char" char=".">&#x02212;42.55</td><td align="char" char=".">810</td></tr><tr><td align="left">8</td><td align="left">45&#x02013;1&#x02013;99&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;44.27</td><td align="char" char=".">0.76</td><td align="char" char=".">&#x02212;0.34</td><td align="char" char=".">&#x02212;43.14</td><td align="char" char=".">790</td></tr><tr><td align="left">9</td><td align="left">H&#x02013;1&#x02013;55&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;60.80</td><td align="char" char=".">3.67</td><td align="char" char=".">&#x02212;10.46</td><td align="char" char=".">&#x02212;46.66</td><td align="char" char=".">650</td></tr><tr><td align="left">10</td><td align="left">H&#x02013;H&#x02013;5&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;44.12</td><td align="char" char=".">&#x02212;0.47</td><td align="char" char=".">&#x02212;4.68</td><td align="char" char=".">&#x02212;39.90</td><td align="char" char=".">940</td></tr><tr><td align="left">11</td><td align="left">4&#x02013;5&#x02013;1&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;45.96</td><td align="char" char=".">&#x02212;0.27</td><td align="char" char=".">&#x02212;6.09</td><td align="char" char=".">&#x02212;40.14</td><td align="char" char=".">930</td></tr><tr><td align="left">12</td><td align="left">33&#x02013;H&#x02013;102&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;49.75</td><td align="char" char=".">0.57</td><td align="char" char=".">1.00</td><td align="char" char=".">&#x02212;50.18</td><td align="char" char=".">540</td></tr><tr><td align="left">13</td><td align="left">33&#x02013;1&#x02013;99&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;49.55</td><td align="char" char=".">0.76</td><td align="char" char=".">&#x02212;3.08</td><td align="char" char=".">&#x02212;45.69</td><td align="char" char=".">690</td></tr><tr><td align="left">14</td><td align="left">14&#x02013;6&#x02013;1&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;48.66</td><td align="char" char=".">&#x02212;0.27</td><td align="char" char=".">&#x02212;6.42</td><td align="char" char=".">&#x02212;42.51</td><td align="char" char=".">820</td></tr><tr><td align="left">15</td><td align="left">14&#x02013;H&#x02013;2&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;46.76</td><td align="char" char=".">0.12</td><td align="char" char=".">&#x02212;5.41</td><td align="char" char=".">&#x02212;41.22</td><td align="char" char=".">880</td></tr><tr><td align="left">16</td><td align="left">33&#x02013;1&#x02013;37&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;47.22</td><td align="char" char=".">2.17</td><td align="char" char=".">&#x02212;0.48</td><td align="char" char=".">&#x02212;44.56</td><td align="char" char=".">730</td></tr><tr><td align="left">17</td><td align="left">33&#x02013;H&#x02013;17&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;46.92</td><td align="char" char=".">0.63</td><td align="char" char=".">&#x02212;0.52</td><td align="char" char=".">&#x02212;45.76</td><td align="char" char=".">680</td></tr><tr><td align="left">18</td><td align="left">12&#x02013;H&#x02013;52&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;39.45</td><td align="char" char=".">1.21</td><td align="char" char=".">&#x02212;6.61</td><td align="char" char=".">&#x02212;31.61</td><td align="char" char=".">1480</td></tr><tr><td align="left">19</td><td align="left">31&#x02013;1&#x02013;63&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;53.54</td><td align="char" char=".">&#x02212;0.31</td><td align="char" char=".">&#x02212;3.02</td><td align="char" char=".">&#x02212;50.84</td><td align="char" char=".">520</td></tr><tr><td align="left">20</td><td align="left">31&#x02013;7&#x02013;4&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;49.53</td><td align="char" char=".">&#x02212;0.04</td><td align="char" char=".">&#x02212;2.20</td><td align="char" char=".">&#x02212;47.38</td><td align="char" char=".">630</td></tr><tr><td align="left">21</td><td align="left">29&#x02013;2&#x02013;106&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;45.44</td><td align="char" char=".">1.56</td><td align="char" char=".">1.92</td><td align="char" char=".">&#x02212;45.80</td><td align="char" char=".">680</td></tr><tr><td align="left">22</td><td align="left">12&#x02013;1&#x02013;106&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;47.88</td><td align="char" char=".">0.37</td><td align="char" char=".">&#x02212;3.25</td><td align="char" char=".">&#x02212;44.25</td><td align="char" char=".">740</td></tr><tr><td align="left">23</td><td align="left">18&#x02013;H&#x02013;106&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;46.70</td><td align="char" char=".">0.65</td><td align="char" char=".">&#x02212;1.26</td><td align="char" char=".">&#x02212;44.78</td><td align="char" char=".">720</td></tr><tr><td align="left">24</td><td align="left">16&#x02013;1&#x02013;106&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;49.96</td><td align="char" char=".">0.07</td><td align="char" char=".">&#x02212;3.50</td><td align="char" char=".">&#x02212;46.38</td><td align="char" char=".">660</td></tr><tr><td align="left">25</td><td align="left">53&#x02013;2&#x02013;2&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;76.38</td><td align="char" char=".">1.37</td><td align="char" char=".">&#x02212;13.87</td><td align="char" char=".">&#x02212;61.12</td><td align="char" char=".">290</td></tr><tr><td align="left">26</td><td align="left">122&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;95.43</td><td align="char" char=".">1.53</td><td align="char" char=".">&#x02212;10.6</td><td align="char" char=".">&#x02212;83.3</td><td align="char" char=".">90</td></tr><tr><td align="left">27</td><td align="left">121&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;68.89</td><td align="char" char=".">0.16</td><td align="char" char=".">&#x02212;9.19</td><td align="char" char=".">&#x02212;59.53</td><td align="char" char=".">320</td></tr><tr><td align="left">28</td><td align="left">53&#x02013;H&#x02013;2&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;75.66</td><td align="char" char=".">0.92</td><td align="char" char=".">&#x02212;11.97</td><td align="char" char=".">&#x02212;62.76</td><td align="char" char=".">270</td></tr><tr><td align="left">29</td><td align="left">53&#x02013;2&#x02013;3&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;77.01</td><td align="char" char=".">1.15</td><td align="char" char=".">&#x02212;13.81</td><td align="char" char=".">&#x02212;62.04</td><td align="char" char=".">280</td></tr><tr><td align="left">30</td><td align="left">124&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;66.93</td><td align="char" char=".">&#x02212;4.80</td><td align="char" char=".">&#x02212;2.48</td><td align="char" char=".">&#x02212;69.24</td><td align="char" char=".">190</td></tr><tr><td align="left">31</td><td align="left">125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;100.28</td><td align="char" char=".">&#x02212;4.18</td><td align="char" char=".">&#x02212;1.85</td><td align="char" char=".">&#x02212;102.61</td><td align="char" char=".">30</td></tr><tr><td align="left">32</td><td align="left">126&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;71.57</td><td align="char" char=".">&#x02212;2.25</td><td align="char" char=".">0.20</td><td align="char" char=".">&#x02212;74.03</td><td align="char" char=".">150</td></tr><tr><td align="left">33</td><td align="left">127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;H</td><td align="char" char=".">&#x02212;108.48</td><td align="char" char=".">&#x02212;0.47</td><td align="char" char=".">&#x02212;2.86</td><td align="char" char=".">&#x02212;106.09</td><td align="char" char=".">30</td></tr><tr><td colspan="7" align="left">&#x000a0;<hr/></td></tr><tr><td align="center">No</td><td align="left">Para 1 (p.SC1)</td><td align="center">&#x00394;&#x00394;<italic>H</italic><sub>MM</sub></td><td align="center">&#x00394;&#x00394;<italic>G</italic><sub>sol</sub></td><td align="center">&#x00394;&#x00394;<italic>TS</italic><sub>vib</sub></td><td align="center">&#x00394;&#x00394;<italic>G</italic><sub>com</sub></td><td align="center"><italic>IC</italic><sub>50</sub><sup>pre</sup></td></tr><tr><td colspan="7" align="left">&#x000a0;<hr/></td></tr><tr><td align="left">34</td><td align="left">32&#x02013;1&#x02013;101&#x02013;H&#x02013;H&#x02013;lki</td><td align="char" char=".">&#x02212;0.53</td><td align="char" char=".">0.31</td><td align="char" char=".">5.30</td><td align="char" char=".">&#x02212;5.51</td><td align="char" char=".">6130</td></tr><tr><td align="left">35</td><td align="left">31&#x02013;2&#x02013;62&#x02013;H&#x02013;H&#x02013;lki</td><td align="char" char=".">2.24</td><td align="char" char=".">&#x02212;0.80</td><td align="char" char=".">0.12</td><td align="char" char=".">1.31</td><td align="char" char=".">8890</td></tr><tr><td align="left">36</td><td align="left">52&#x02013;H&#x02013;101&#x02013;H&#x02013;H&#x02013;lki</td><td align="char" char=".">&#x02212;0.57</td><td align="char" char=".">0.05</td><td align="char" char=".">&#x02212;0.43</td><td align="char" char=".">&#x02212;0.08</td><td align="char" char=".">8230</td></tr><tr><td align="left">37</td><td align="left">53&#x02013;1&#x02013;29&#x02013;H&#x02013;H&#x02013;lki</td><td align="char" char=".">&#x02212;4.13</td><td align="char" char=".">1.19</td><td align="char" char=".">&#x02212;0.29</td><td align="char" char=".">&#x02212;2.64</td><td align="char" char=".">7170</td></tr><tr><td align="left">38</td><td align="left">4&#x02013;8&#x02013;31&#x02013;H&#x02013;H&#x02013;lki</td><td align="char" char=".">1.75</td><td align="char" char=".">&#x02212;0.12</td><td align="char" char=".">&#x02212;0.65</td><td align="char" char=".">2.29</td><td align="char" char=".">9370</td></tr><tr><td>&#x000a0;</td><td colspan="6" align="left">Ortho 2 (o.SC1)</td></tr><tr><td colspan="7" align="left">&#x000a0;<hr/></td></tr><tr><td align="left">39</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;33&#x02013;4&#x02013;29</td><td align="char" char=".">&#x02212;41.31</td><td align="char" char=".">&#x02212;3.01</td><td align="char" char=".">1.85</td><td align="char" char=".">&#x02212;46.18</td><td align="char" char=".">670</td></tr><tr><td align="left">40</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;16&#x02013;1&#x02013;32</td><td align="char" char=".">&#x02212;42.10</td><td align="char" char=".">&#x02212;3.74</td><td align="char" char=".">&#x02212;2.16</td><td align="char" char=".">&#x02212;43.68</td><td align="char" char=".">770</td></tr><tr><td align="left">41</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;33&#x02013;H&#x02013;37</td><td align="char" char=".">&#x02212;40.09</td><td align="char" char=".">&#x02212;1.69</td><td align="char" char=".">0.12</td><td align="char" char=".">&#x02212;41.90</td><td align="char" char=".">840</td></tr><tr><td align="left">42</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;15&#x02013;H&#x02013;1</td><td align="char" char=".">&#x02212;38.16</td><td align="char" char=".">&#x02212;3.96</td><td align="char" char=".">&#x02212;5.84</td><td align="char" char=".">&#x02212;36.28</td><td align="char" char=".">1&#x000a0;150</td></tr><tr><td align="left">43</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;9&#x02013;1&#x02013;93</td><td align="char" char=".">&#x02212;36.42</td><td align="char" char=".">&#x02212;5.15</td><td align="char" char=".">&#x02212;3.76</td><td align="char" char=".">&#x02212;37.81</td><td align="char" char=".">1&#x000a0;060</td></tr><tr><td align="left">44</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;29&#x02013;H&#x02013;2</td><td align="char" char=".">&#x02212;36.90</td><td align="char" char=".">&#x02212;2.59</td><td align="char" char=".">0.49</td><td align="char" char=".">&#x02212;39.98</td><td align="char" char=".">940</td></tr><tr><td align="left">45</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;18&#x02013;H&#x02013;31</td><td align="char" char=".">&#x02212;41.11</td><td align="char" char=".">&#x02212;4.09</td><td align="char" char=".">0.19</td><td align="char" char=".">&#x02212;45.40</td><td align="char" char=".">700</td></tr><tr><td align="left">46</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;33&#x02013;H&#x02013;38</td><td align="char" char=".">&#x02212;41.06</td><td align="char" char=".">&#x02212;2.68</td><td align="char" char=".">&#x02212;0.62</td><td align="char" char=".">&#x02212;43.12</td><td align="char" char=".">790</td></tr><tr><td align="left">47</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;53&#x02013;H&#x02013;30</td><td align="char" char=".">&#x02212;43.70</td><td align="char" char=".">&#x02212;4.14</td><td align="char" char=".">&#x02212;2.52</td><td align="char" char=".">&#x02212;45.33</td><td align="char" char=".">700</td></tr><tr><td align="left">48</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;4&#x02013;6&#x02013;93</td><td align="char" char=".">&#x02212;38.33</td><td align="char" char=".">&#x02212;2.03</td><td align="char" char=".">&#x02212;4.01</td><td align="char" char=".">&#x02212;36.34</td><td align="char" char=".">1&#x000a0;140</td></tr><tr><td align="left">49</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;2&#x02013;5&#x02013;31</td><td align="char" char=".">&#x02212;38.76</td><td align="char" char=".">&#x02212;4.17</td><td align="char" char=".">&#x02212;1.63</td><td align="char" char=".">&#x02212;41.30</td><td align="char" char=".">870</td></tr><tr><td align="left">50</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;4&#x02013;7&#x02013;32</td><td align="char" char=".">&#x02212;38.83</td><td align="char" char=".">&#x02212;5.59</td><td align="char" char=".">&#x02212;4.58</td><td align="char" char=".">&#x02212;39.84</td><td align="char" char=".">940</td></tr><tr><td align="left">51</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;4&#x02013;6&#x02013;38</td><td align="char" char=".">&#x02212;38.95</td><td align="char" char=".">&#x02212;3.98</td><td align="char" char=".">&#x02212;1.80</td><td align="char" char=".">&#x02212;41.13</td><td align="char" char=".">880</td></tr><tr><td align="left">52</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;1&#x02013;6&#x02013;H</td><td align="char" char=".">&#x02212;35.94</td><td align="char" char=".">&#x02212;4.94</td><td align="char" char=".">&#x02212;5.63</td><td align="char" char=".">&#x02212;35.25</td><td align="char" char=".">1210</td></tr><tr><td align="left">53</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;1&#x02013;2&#x02013;102</td><td align="char" char=".">&#x02212;39.53</td><td align="char" char=".">&#x02212;2.57</td><td align="char" char=".">&#x02212;0.92</td><td align="char" char=".">&#x02212;41.18</td><td align="char" char=".">880</td></tr><tr><td align="left">54</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;6&#x02013;7&#x02013;31</td><td align="char" char=".">&#x02212;37.56</td><td align="char" char=".">&#x02212;4.91</td><td align="char" char=".">&#x02212;1.72</td><td align="char" char=".">&#x02212;40.75</td><td align="char" char=".">900</td></tr><tr><td align="left">55</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;2&#x02013;H&#x02013;29</td><td align="char" char=".">&#x02212;37.12</td><td align="char" char=".">&#x02212;4.87</td><td align="char" char=".">&#x02212;2.10</td><td align="char" char=".">&#x02212;39.89</td><td align="char" char=".">940</td></tr><tr><td align="left">56</td><td align="left">lki&#x02013;H&#x02013;H&#x02013;1&#x02013;4&#x02013;106</td><td align="char" char=".">&#x02212;53.16</td><td align="char" char=".">&#x02212;3.05</td><td align="char" char=".">&#x02212;6.37</td><td align="char" char=".">&#x02212;49.84</td><td align="char" char=".">550</td></tr></tbody></table><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">No</th><th align="left">Meta 2 (m.SC2)</th><th align="center">&#x00394;&#x00394;<italic>H</italic><sub>MM</sub></th><th align="center">&#x00394;&#x00394;<italic>G</italic><sub>sol</sub></th><th align="center">&#x00394;&#x00394;<italic>TS</italic><sub>vib</sub></th><th align="center">&#x00394;&#x00394;<italic>G</italic><sub>com</sub></th><th align="center"><italic>IC</italic><sub>50</sub><sup>pre</sup></th></tr></thead><tbody valign="top"><tr><td align="left">57</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;33&#x02013;4&#x02013;29</td><td align="char" char=".">&#x02212;45.50</td><td align="char" char=".">&#x02212;1.61</td><td align="char" char=".">&#x02212;0.12</td><td align="char" char=".">&#x02212;46.99</td><td align="char" char=".">640</td></tr><tr><td align="left">58</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;33&#x02013;H&#x02013;37</td><td align="char" char=".">&#x02212;46.73</td><td align="char" char=".">&#x02212;0.43</td><td align="char" char=".">0.98</td><td align="char" char=".">&#x02212;48.15</td><td align="char" char=".">600</td></tr><tr><td align="left">59</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;15&#x02013;H&#x02013;1</td><td align="char" char=".">&#x02212;44.73</td><td align="char" char=".">&#x02212;1.07</td><td align="char" char=".">&#x02212;6.52</td><td align="char" char=".">&#x02212;39.28</td><td align="char" char=".">970</td></tr><tr><td align="left">60</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;29&#x02013;H&#x02013;2</td><td align="char" char=".">&#x02212;44.41</td><td align="char" char=".">&#x02212;1.59</td><td align="char" char=".">0.32</td><td align="char" char=".">&#x02212;46.33</td><td align="char" char=".">660</td></tr><tr><td align="left">61</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;18&#x02013;H&#x02013;31</td><td align="char" char=".">&#x02212;43.73</td><td align="char" char=".">&#x02212;0.95</td><td align="char" char=".">&#x02212;3.32</td><td align="char" char=".">&#x02212;41.36</td><td align="char" char=".">870</td></tr><tr><td align="left">62</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;33&#x02013;H&#x02013;38</td><td align="char" char=".">&#x02212;45.55</td><td align="char" char=".">&#x02212;1.57</td><td align="char" char=".">&#x02212;0.28</td><td align="char" char=".">&#x02212;46.85</td><td align="char" char=".">640</td></tr><tr><td align="left">63</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;16&#x02013;6&#x02013;95</td><td align="char" char=".">&#x02212;47.00</td><td align="char" char=".">&#x02212;1.36</td><td align="char" char=".">&#x02212;1.35</td><td align="char" char=".">&#x02212;47.01</td><td align="char" char=".">640</td></tr><tr><td align="left">64</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;50&#x02013;H&#x02013;31</td><td align="char" char=".">&#x02212;45.63</td><td align="char" char=".">0.42</td><td align="char" char=".">&#x02212;3.10</td><td align="char" char=".">&#x02212;42.10</td><td align="char" char=".">830</td></tr><tr><td align="left">65</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;H&#x02013;1&#x02013;46</td><td align="char" char=".">&#x02212;42.57</td><td align="char" char=".">&#x02212;1.87</td><td align="char" char=".">&#x02212;4.77</td><td align="char" char=".">&#x02212;39.67</td><td align="char" char=".">950</td></tr><tr><td align="left">66</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;H&#x02013;7&#x02013;31</td><td align="char" char=".">&#x02212;40.87</td><td align="char" char=".">&#x02212;2.81</td><td align="char" char=".">&#x02212;1.01</td><td align="char" char=".">&#x02212;42.66</td><td align="char" char=".">810</td></tr><tr><td align="left">67</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;51&#x02013;H&#x02013;30</td><td align="char" char=".">&#x02212;48.12</td><td align="char" char=".">&#x02212;2.20</td><td align="char" char=".">0.68</td><td align="char" char=".">&#x02212;51.00</td><td align="char" char=".">510</td></tr><tr><td align="left">68</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;1&#x02013;1&#x02013;29</td><td align="char" char=".">&#x02212;39.50</td><td align="char" char=".">&#x02212;2.10</td><td align="char" char=".">&#x02212;1.34</td><td align="char" char=".">&#x02212;40.27</td><td align="char" char=".">920</td></tr><tr><td align="left">69</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;4&#x02013;6&#x02013;93</td><td align="char" char=".">&#x02212;42.95</td><td align="char" char=".">&#x02212;1.69</td><td align="char" char=".">&#x02212;3.28</td><td align="char" char=".">&#x02212;41.37</td><td align="char" char=".">870</td></tr><tr><td align="left">70</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;2&#x02013;5&#x02013;31</td><td align="char" char=".">&#x02212;41.22</td><td align="char" char=".">&#x02212;1.24</td><td align="char" char=".">&#x02212;2.76</td><td align="char" char=".">&#x02212;39.69</td><td align="char" char=".">950</td></tr><tr><td align="left">71</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;4&#x02013;7&#x02013;32</td><td align="char" char=".">&#x02212;42.49</td><td align="char" char=".">&#x02212;1.60</td><td align="char" char=".">&#x02212;4.56</td><td align="char" char=".">&#x02212;39.52</td><td align="char" char=".">960</td></tr><tr><td align="left">72</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;4&#x02013;6&#x02013;38</td><td align="char" char=".">&#x02212;42.63</td><td align="char" char=".">&#x02212;2.52</td><td align="char" char=".">&#x02212;4.73</td><td align="char" char=".">&#x02212;40.41</td><td align="char" char=".">920</td></tr><tr><td align="left">73</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;1&#x02013;2&#x02013;102</td><td align="char" char=".">&#x02212;42.14</td><td align="char" char=".">&#x02212;0.83</td><td align="char" char=".">&#x02212;3.42</td><td align="char" char=".">&#x02212;39.55</td><td align="char" char=".">960</td></tr><tr><td align="left">74</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;6&#x02013;7&#x02013;31</td><td align="char" char=".">&#x02212;41.44</td><td align="char" char=".">&#x02212;1.53</td><td align="char" char=".">&#x02212;2.26</td><td align="char" char=".">&#x02212;40.72</td><td align="char" char=".">900</td></tr><tr><td align="left">75</td><td align="left">H&#x02013;lki&#x02013;H&#x02013;2&#x02013;H&#x02013;29</td><td align="char" char=".">&#x02212;42.23</td><td align="char" char=".">&#x02212;1.72</td><td align="char" char=".">&#x02212;3.29</td><td align="char" char=".">&#x02212;40.65</td><td align="char" char=".">900</td></tr><tr><td align="left">76<hr/></td><td align="left">H&#x02013;lki&#x02013;H&#x02013;1&#x02013;4&#x02013;106<hr/></td><td align="char" char=".">&#x02212;44.34<hr/></td><td align="char" char=".">&#x02212;1.22<hr/></td><td align="char" char=".">&#x02212;5.99<hr/></td><td align="char" char=".">&#x02212;39.57<hr/></td><td align="char" char=".">960<hr/></td></tr><tr><td align="left">No<hr/></td><td align="left">Para 2 (p.SC2)<hr/></td><td align="center">&#x00394;&#x00394;<italic>H</italic><sub>MM</sub><hr/></td><td align="center">&#x00394;&#x00394;<italic>G</italic><sub>sol</sub><hr/></td><td align="center">&#x00394;&#x00394;<italic>TS</italic><sub>vib</sub><hr/></td><td align="center">&#x00394;&#x00394;<italic>G</italic><sub>com</sub><hr/></td><td align="center"><italic>IC</italic><sub>50</sub><sup>pre</sup><hr/></td></tr><tr><td align="left">77</td><td align="left">H&#x02013;H&#x02013;lki&#x02013;45&#x02013;8&#x02013;106</td><td align="char" char=".">3.62</td><td align="char" char=".">&#x02212;0.94</td><td align="char" char=".">&#x02212;1.54</td><td align="char" char=".">4.22</td><td align="char" char=".">10410</td></tr><tr><td align="left">78</td><td align="left">H&#x02013;H&#x02013;lki&#x02013;52&#x02013;H&#x02013;1</td><td align="char" char=".">0.38</td><td align="char" char=".">&#x02212;2.85</td><td align="char" char=".">&#x02212;4.56</td><td align="char" char=".">2.09</td><td align="char" char=".">9270</td></tr><tr><td align="left">79</td><td align="left">H&#x02013;H&#x02013;lki&#x02013;52&#x02013;6&#x02013;62</td><td align="char" char=".">1.93</td><td align="char" char=".">&#x02212;1.28</td><td align="char" char=".">&#x02212;3.36</td><td align="char" char=".">4.00</td><td align="char" char=".">10290</td></tr><tr><td align="left">80</td><td align="left">H&#x02013;H&#x02013;lki&#x02013;4&#x02013;8&#x02013;4</td><td align="char" char=".">0.29</td><td align="char" char=".">&#x02212;1.97</td><td align="char" char=".">&#x02212;6.02</td><td align="char" char=".">4.33</td><td align="char" char=".">10480</td></tr><tr><td align="left">81</td><td align="left">H&#x02013;H&#x02013;lki&#x02013;1&#x02013;5&#x02013;94</td><td align="char" char=".">4.80</td><td align="char" char=".">&#x02212;1.67</td><td align="char" char=".">1.31</td><td align="char" char=".">1.81</td><td align="char" char=".">9130</td></tr></tbody></table><table-wrap-foot><fn id="TF19"><p>
<sup>a</sup>&#x00394;&#x00394;<italic>H</italic>
<sub>MM</sub> (kcal&#x022c5;mol<sup>&#x02212;1</sup>) is the relative enthalpic contribution to the GFE change of FP-2:HLCIC complex formation &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> (for details see footnote of <xref rid="t0002" ref-type="table">Table 2</xref>).</p></fn><fn id="TF20"><p>
<sup>b</sup>&#x00394;&#x00394;<italic>G</italic>
<sub>sol</sub> (kcal&#x022c5;mol<sup>&#x02212;1</sup>) is the relative solvation GFE contribution to &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub>.</p></fn><fn id="TF21"><p>
<sup>c</sup>&#x00394;&#x00394;<italic>TS</italic>
<sub>vib</sub> (kcal&#x022c5;mol<sup>&#x02212;1</sup>) is the relative entropic (vibrational) contribution to &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub>.</p></fn><fn id="TF22"><p>
<sup>d</sup>&#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> (kcal&#x022c5;mol<sup>&#x02212;1</sup>) the relative GFE change of the FP-2:HLCIC complex formation &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> = &#x00394;&#x00394;<italic>H</italic>
<sub>MM</sub> + &#x00394;&#x00394;<italic>G</italic>
<sub>sol</sub> + &#x00394;&#x00394;<italic>TS</italic>
<sub>vib</sub>.</p></fn><fn id="TF23"><p>
<sup>e</sup>
<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> (nM) is the predicted half-maximal inhibitory concentration of HLCIC towards FP-2 of <italic>Pf</italic> calculated from &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> using correlation equation (B) (<xref rid="t0003" ref-type="table">Table 3</xref>).</p></fn><fn id="TF24"><p>
<sup>f</sup>
<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup> is given for the reference inhibitor HLCIC1<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref> instead of <italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> (nM).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0011" orientation="portrait" position="float"><label>Table 11.</label><caption><p>GFE of FP-2:HLCIC complex formation and its components for the 33 virtually designed HLCIC with intuitive P2 substitution (<italic>R</italic>
<sub>6</sub>-group) exploring the S2 pocket in addition to S1, S1&#x02019;, and S3.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th rowspan="2" align="left">No</th><th align="center">Analogues<hr/></th><th align="center">&#x00394;&#x00394;<italic>H</italic><sub>MM</sub><hr/></th><th align="center">&#x00394;&#x00394;<italic>G</italic><sub>sol</sub><hr/></th><th align="center">&#x00394;&#x00394;<italic>TS</italic><sub>vib</sub><hr/></th><th align="center">&#x00394;&#x00394;<italic>G</italic><sub>com</sub><hr/></th><th align="center"><italic>IC</italic><sub>50</sub><sup>pre</sup><hr/></th></tr><tr><th align="center">HLCIC1</th><th align="center" char=".">0</th><th align="center" char=".">0</th><th align="center" char=".">0</th><th align="center" char=".">0</th><th align="center" char=".">6800</th></tr></thead><tbody valign="top"><tr><td align="left">82</td><td align="left">125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;128</td><td align="char" char=".">&#x02212;113.67</td><td align="char" char=".">&#x02212;2.72</td><td align="char" char=".">2.83</td><td align="char" char=".">&#x02212;119.23</td><td align="char" char=".">13</td></tr><tr><td align="left">83</td><td align="left">125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;129</td><td align="char" char=".">&#x02212;111.20</td><td align="char" char=".">&#x02212;1.73</td><td align="char" char=".">3.26</td><td align="char" char=".">&#x02212;116.20</td><td align="char" char=".">15</td></tr><tr><td align="left">84</td><td align="left">125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;134</td><td align="char" char=".">&#x02212;110.06</td><td align="char" char=".">&#x02212;1.39</td><td align="char" char=".">1.87</td><td align="char" char=".">&#x02212;113.33</td><td align="char" char=".">18</td></tr><tr><td align="left">85</td><td align="left">126&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;128</td><td align="char" char=".">&#x02212;84.96</td><td align="char" char=".">0.07</td><td align="char" char=".">3.59</td><td align="char" char=".">&#x02212;88.48</td><td align="char" char=".">68</td></tr><tr><td align="left">86</td><td align="left">126&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;129</td><td align="char" char=".">&#x02212;84.46</td><td align="char" char=".">0.97</td><td align="char" char=".">3.18</td><td align="char" char=".">&#x02212;86.66</td><td align="char" char=".">75</td></tr><tr><td align="left">87</td><td align="left">126&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;134</td><td align="char" char=".">&#x02212;79.04</td><td align="char" char=".">0.83</td><td align="char" char=".">3.95</td><td align="char" char=".">&#x02212;82.16</td><td align="char" char=".">95</td></tr><tr><td align="left">88</td><td align="left">127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;128</td><td align="char" char=".">&#x02212;119.71</td><td align="char" char=".">2.17</td><td align="char" char=".">1.45</td><td align="char" char=".">&#x02212;118.99</td><td align="char" char=".">13</td></tr><tr><td align="left">89</td><td align="left">127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;129</td><td align="char" char=".">&#x02212;117.15</td><td align="char" char=".">2.79</td><td align="char" char=".">2.60</td><td align="char" char=".">&#x02212;116.97</td><td align="char" char=".">15</td></tr><tr><td align="left">90</td><td align="left">127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;134</td><td align="char" char=".">&#x02212;113.51</td><td align="char" char=".">2.86</td><td align="char" char=".">3.15</td><td align="char" char=".">&#x02212;113.80</td><td align="char" char=".">17</td></tr><tr><td align="left">91</td><td align="left">53&#x02013;2&#x02013;2&#x02013;H&#x02013;lki&#x02013;128</td><td align="char" char=".">&#x02212;76.09</td><td align="char" char=".">1.53</td><td align="char" char=".">&#x02212;4.86</td><td align="char" char=".">&#x02212;69.70</td><td align="char" char=".">187</td></tr><tr><td align="left">92</td><td align="left">53&#x02013;2&#x02013;2&#x02013;H&#x02013;lki&#x02013;129</td><td align="char" char=".">&#x02212;73.74</td><td align="char" char=".">1.93</td><td align="char" char=".">&#x02212;2.96</td><td align="char" char=".">&#x02212;68.86</td><td align="char" char=".">196</td></tr><tr><td align="left">93</td><td align="left">122&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;130</td><td align="char" char=".">&#x02212;107.89</td><td align="char" char=".">0.72</td><td align="char" char=".">&#x02212;1.05</td><td align="char" char=".">&#x02212;106.12</td><td align="char" char=".">26</td></tr><tr><td align="left">94</td><td align="left">53&#x02013;H&#x02013;2&#x02013;H&#x02013;lki&#x02013;128</td><td align="char" char=".">&#x02212;82.57</td><td align="char" char=".">2.57</td><td align="char" char=".">&#x02212;1.77</td><td align="char" char=".">&#x02212;78.22</td><td align="char" char=".">118</td></tr><tr><td align="left">95</td><td align="left">53&#x02013;H&#x02013;2&#x02013;H&#x02013;lki&#x02013;136</td><td align="char" char=".">&#x02212;72.35</td><td align="char" char=".">2.61</td><td align="char" char=".">&#x02212;4.93</td><td align="char" char=".">&#x02212;64.81</td><td align="char" char=".">245</td></tr><tr><td align="left">96</td><td align="left">51&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;128</td><td align="char" char=".">&#x02212;76.64</td><td align="char" char=".">1.84</td><td align="char" char=".">&#x02212;2.59</td><td align="char" char=".">&#x02212;72.22</td><td align="char" char=".">164</td></tr><tr><td align="left">97</td><td align="left">51&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;133</td><td align="char" char=".">&#x02212;68.35</td><td align="char" char=".">1.15</td><td align="char" char=".">&#x02212;2.93</td><td align="char" char=".">&#x02212;64.27</td><td align="char" char=".">252</td></tr><tr><td align="left">98</td><td align="left">33&#x02013;H&#x02013;102&#x02013;H&#x02013;lki&#x02013;131</td><td align="char" char=".">&#x02212;74.65</td><td align="char" char=".">3.54</td><td align="char" char=".">5.88</td><td align="char" char=".">&#x02212;77.00</td><td align="char" char=".">126</td></tr><tr><td align="left">99</td><td align="left">33&#x02013;H&#x02013;102&#x02013;H&#x02013;lki&#x02013;134</td><td align="char" char=".">&#x02212;70.26</td><td align="char" char=".">3.83</td><td align="char" char=".">6.98</td><td align="char" char=".">&#x02212;73.41</td><td align="char" char=".">153</td></tr><tr><td align="left">100</td><td align="left">31&#x02013;1&#x02013;63&#x02013;H&#x02013;lki&#x02013;128</td><td align="char" char=".">&#x02212;67.37</td><td align="char" char=".">1.83</td><td align="char" char=".">0.36</td><td align="char" char=".">&#x02212;65.91</td><td align="char" char=".">230</td></tr><tr><td align="left">101</td><td align="left">31&#x02013;1&#x02013;63&#x02013;H&#x02013;lki&#x02013;129</td><td align="char" char=".">&#x02212;65.27</td><td align="char" char=".">2.31</td><td align="char" char=".">&#x02212;0.70</td><td align="char" char=".">&#x02212;62.26</td><td align="char" char=".">281</td></tr><tr><td align="left">102</td><td align="left">51&#x02013;H&#x02013;30&#x02013;H&#x02013;lki&#x02013;131</td><td align="char" char=".">&#x02212;80.47</td><td align="char" char=".">&#x02212;1.39</td><td align="char" char=".">2.96</td><td align="char" char=".">&#x02212;84.82</td><td align="char" char=".">82</td></tr><tr><td align="left">103</td><td align="left">51&#x02013;H&#x02013;30&#x02013;H&#x02013;lki&#x02013;136</td><td align="char" char=".">&#x02212;81.95</td><td align="char" char=".">&#x02212;0.23</td><td align="char" char=".">4.15</td><td align="char" char=".">&#x02212;86.33</td><td align="char" char=".">76</td></tr><tr><td align="left">104</td><td align="left">31&#x02013;H&#x02013;100&#x02013;lki&#x02013;H&#x02013;128</td><td align="char" char=".">&#x02212;73.53</td><td align="char" char=".">0.58</td><td align="char" char=".">9.39</td><td align="char" char=".">&#x02212;82.34</td><td align="char" char=".">94</td></tr><tr><td align="left">105</td><td align="left">31&#x02013;H&#x02013;100&#x02013;lki&#x02013;H&#x02013;129</td><td align="char" char=".">&#x02212;65.73</td><td align="char" char=".">0.96</td><td align="char" char=".">9.24</td><td align="char" char=".">&#x02212;74.02</td><td align="char" char=".">148</td></tr><tr><td align="left">106</td><td align="left">31&#x02013;H&#x02013;100&#x02013;lki&#x02013;H&#x02013;132</td><td align="char" char=".">&#x02212;67.83</td><td align="char" char=".">2.41</td><td align="char" char=".">1.39</td><td align="char" char=".">&#x02212;66.81</td><td align="char" char=".">219</td></tr><tr><td align="left">107</td><td align="left">1&#x02013;4&#x02013;106&#x02013;lki&#x02013;H&#x02013;131</td><td align="char" char=".">&#x02212;70.26</td><td align="char" char=".">2.91</td><td align="char" char=".">&#x02212;0.52</td><td align="char" char=".">&#x02212;66.84</td><td align="char" char=".">219</td></tr><tr><td align="left">108</td><td align="left">1&#x02013;4&#x02013;106&#x02013;lki&#x02013;H&#x02013;133</td><td align="char" char=".">&#x02212;61.56</td><td align="char" char=".">2.57</td><td align="char" char=".">&#x02212;0.44</td><td align="char" char=".">&#x02212;58.55</td><td align="char" char=".">344</td></tr><tr><td align="left">109</td><td align="left">125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;132</td><td align="char" char=".">&#x02212;108.80</td><td align="char" char=".">&#x02212;0.52</td><td align="char" char=".">&#x02212;4.86</td><td align="char" char=".">&#x02212;104.47</td><td align="char" char=".">29</td></tr><tr><td align="left">110</td><td align="left">125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;133</td><td align="char" char=".">&#x02212;110.12</td><td align="char" char=".">&#x02212;2.09</td><td align="char" char=".">&#x02212;0.96</td><td align="char" char=".">&#x02212;111.26</td><td align="char" char=".">20</td></tr><tr><td align="left">111</td><td align="left">125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;137</td><td align="char" char=".">&#x02212;114.41</td><td align="char" char=".">&#x02212;1.70</td><td align="char" char=".">&#x02212;0.29</td><td align="char" char=".">&#x02212;115.82</td><td align="char" char=".">16</td></tr><tr><td align="left">112</td><td align="left">127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;132</td><td align="char" char=".">&#x02212;113.82</td><td align="char" char=".">3.33</td><td align="char" char=".">&#x02212;1.74</td><td align="char" char=".">&#x02212;108.76</td><td align="char" char=".">23</td></tr><tr><td align="left">113</td><td align="left">127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;133</td><td align="char" char=".">&#x02212;115.25</td><td align="char" char=".">2.25</td><td align="char" char=".">&#x02212;1.23</td><td align="char" char=".">&#x02212;111.77</td><td align="char" char=".">19</td></tr><tr><td align="left">114</td><td align="left">127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;137</td><td align="char" char=".">&#x02212;120.03</td><td align="char" char=".">2.59</td><td align="char" char=".">&#x02212;1.40</td><td align="char" char=".">&#x02212;116.04</td><td align="char" char=".">15</td></tr></tbody></table></table-wrap><p>In order to identify which substituents from <xref rid="t0009" ref-type="table">Table 9</xref> lead to new inhibitor candidates with high predicted potencies towards the FP-2, we have prepared histograms of the frequency of occurrence of the <italic>R</italic>
<sub>1</sub> to <italic>R</italic>
<sub>6</sub> groups in these 81 HLCIC virtual hits (<xref ref-type="fig" rid="F0008">Figure 8</xref>). Analysis of the histograms showed that the highest frequency of occurrence among the <italic>R</italic>
<sub>1</sub>-groups displayed the fragments 31, 33, and 53 (<xref rid="t0009" ref-type="table">Table 9</xref>). In case of <italic>R</italic>
<sub>2</sub>-groups fragments 1 and 2; for the <italic>R</italic>
<sub>3</sub>-groups fragments 1, 2, and 106; for the <italic>R</italic>
<sub>4</sub>-groups fragments 1, 2, 4, and 33 against 1 (4), 4 (4), 6 (7), and 7 (5) for R5 while the R6 group include chiefly fragments 1 (4), 29 (5), 31 (7), and 38 (4).</p><fig id="F0008" orientation="portrait" position="float"><label>Figure 8.</label><caption><p>Histograms of frequency of occurrence of individual <italic>R</italic>
<sub>1</sub>&#x02013;<italic>R</italic>
<sub>6</sub> groups in the 81 selected analogues mapping to the five-feature pharmacophore hypothesis Hypo1 (for fragments numbering see <xref rid="t0009" ref-type="table">Table 9</xref>).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1564288_F0008_C"/></fig></sec><sec id="s0016"><label>3.2.</label><title>Discussion</title><p>Training set of 15 HLCIC inhibitors and observed half-maximal inhibitory concentrations <italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>
<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref> were employed to derive QSAR model of FP-2 inhibition, which uses a single descriptor determined by molecular modelling (GFE of FP-2:HLCIC complex formation, &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub>) and crystal structure of the FP-2 of <italic>Pf</italic> in complex with epoxysuccinate E64 (3BPF)<xref rid="CIT0015" ref-type="bibr">
<sup>15</sup>
</xref>. This statistically significant QSAR model confirmed the validity of our 3D models of HLCIC inhibitors and the mode of their binding to the active site of the FP-2 of <italic>Pf</italic>. Then a 3D pharmacophore (PH4) model of FP-2 inhibition was prepared for the bound conformations of HLCIC and was further used for screening of a large virtual combinatorial library of HLCIC analogues with the aim to identify more potent and bioavailable FP-2 inhibitors. The activities of the identified putative inhibitors and analogues proposed by structure-based design (<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>) were predicted by linear QSAR regression equation (B) (<xref rid="t0003" ref-type="table">Table 3</xref>) and cross-checked by the PH4 regression equation (D) (<xref rid="t0008" ref-type="table">Table 8</xref>).</p><sec id="s0017"><label>3.2.1.</label><title>QSAR model</title><p>The robustness of the single descriptor QSAR model was analyzed by assessing the role of the individual components of GFE of the FP-2:HLCIC complex formation &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub>, namely the enthalpic, solvation and approximate entropic contributions. The relevance of the enthalpic contribution &#x00394;&#x00394;<italic>H</italic>
<sub>MM</sub> to GFE was well confirmed by the quality of the regression (A) (<xref rid="t0003" ref-type="table">Table 3</xref>), indicating that a large part (91%) of the variation of the <italic>IC</italic>
<sub>50</sub>
<sup>exp</sup> can be explained by intermolecular interactions, which can be traced back to contributions of active site pockets (Sn) as well as individual residues, <italic>E</italic>
<sub>int</sub> (<xref rid="t0006" ref-type="table">Table 6</xref>; <xref ref-type="fig" rid="F0006">Figure 6</xref>). Addition of the solvation term &#x00394;&#x00394;<italic>G</italic>
<sub>sol</sub> maintained the relationship level between the experimental data and the modelling results. Finally, the validity of the model was increased by adding the &#x00394;&#x00394;<italic>TS</italic>
<sub>vib</sub> term that describes the loss of the inhibitor vibrational entropy upon enzyme binding, which explained 93% of the variation of the <italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>. This last contribution is considered to be one of the most reliable indicators of the predictive power of QSAR models as reported by Freire et&#x000a0;al.<xref rid="CIT0043" ref-type="bibr">
<sup>43</sup>
</xref>. The VS of 3 HLCICV inhibitors not included into the training set (<xref rid="t0002" ref-type="table">Table 2</xref>) confirmed good correlation between the &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> and the observed activities <italic>IC</italic>
<sub>50</sub>
<sup>exp</sup>
<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref> since the ratio between computed and experimental potencies p<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>/p<italic>IC</italic>
<sub>50</sub>
<sup>exp</sup> was close to one. Therefore, the QSAR correlation equation (B) and computed relative GFE &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> can be used for prediction of inhibitory potencies <italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> of new HLCIC analogues against the FP-2 of <italic>Pf</italic>, since they share the same binding mode as the training set<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref>.</p></sec><sec id="s0018"><label>3.2.2.</label><title>Binding mode of FP-2 inhibitors</title><p>Besides the robustness of the QSAR model, the analysis of the interactions between the HLCIC and active site residues revealed the key interactions responsible for the HLCIC affinity to FP-2, such as hydrogen bonds, van der Waals interactions, hydrophobic contacts, etc. As displayed in the 2D and 3D schemes of <xref ref-type="fig" rid="F0004">Figure 4</xref>, the binding of HLCIC1 to the active site of FP-2 is supported by the following interactions: HB with His174 and stacking interaction with Tyr78. To verify whether also other stronger interactions co-determine the binding mode of HLCIC to FP-2 active site and aid structure-based design of new analogues, interaction energies <italic>E</italic>
<sub>int</sub> between active site residues and HLCIC were computed (<xref rid="t0006" ref-type="table">Table 6</xref>). The peptidyl structure of HLCIC shed some light on the structural features required for the binding affinity improvement, taking advantage of the S pockets filling (<xref ref-type="fig" rid="F0006">Figure 6</xref>). The computed overall interaction energy complexes FP-2:HLCICx correlated with the observed inhibitory potencies <italic>IC</italic>
<sub>50</sub>
<sup>exp</sup> of the training set HLCIC inhibitors (<xref ref-type="fig" rid="F0005">Figure 5</xref>; <xref rid="t0005" ref-type="table">Table 5</xref>). In particular, the correlation between the van der Waals component of <italic>E</italic>
<sub>int</sub> and <italic>IC</italic>
<sub>50</sub>
<sup>exp</sup> pointed to the &#x003c0;&#x02013;&#x003c0; stacking interaction involving the isatin moiety of the inhibitor and Tyr78.</p><p>The S2 pocket filling and interaction energy contribution shows dominant effect on the FP-2 inhibition as reported previously<xref rid="CIT0010" ref-type="bibr">
<sup>10</sup>
</xref>. On the other hand, comparison of the contributions to <italic>E</italic>
<sub>int</sub> between the most active inhibitor HLCIC1 and less active one HLCIC6, corresponds to the trend of activities, but cannot explain the large gap in their inhibitory potencies (1224%). However, in a recent work, we succeeded in justifying the observed 37.5% jump in experimental biological activity between methylphosphonic arginine and hydroxamic acid derivative, both <italic>Pf</italic> Leucyl aminopeptidase (<italic>Pf</italic>A-M17) inhibitors by the enzyme active site residues contribution to <italic>E</italic>
<sub>int</sub> at a level of 35%<xref rid="CIT0044" ref-type="bibr">
<sup>44</sup>
</xref>. Therefore, essential structural information needed for the design of novel potent HLCIC analogues was derived from a more predictive descriptor &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub>. New inhibitor candidates were selected according to the workflow (<xref ref-type="fig" rid="F0002">Figure 2</xref>), by virtual screening from a diverse VL of analogues with the active site pockets filling as the central structural requirement displayed by the pharmacophore model of FP-2 inhibition provided by the one descriptor (GFE) QSAR model (<xref rid="t0003" ref-type="table">Table 3</xref>; <xref ref-type="fig" rid="F0003">Figure 3</xref>).</p></sec><sec id="s0019"><title>
<italic>3.2.3. Analysis of new inhibitors from</italic> in silico <italic>screening</italic>
</title><p>An analysis of structural requirement for FP-2 inhibition at the level of hydrophobic contacts with the active site revealed that the P2 substituent, namely the <italic>R</italic>
<sub>6</sub>-group in the training set insufficiently explored the S2 pocket of the FP-2 active site. Therefore, new HLCIC analogues that match the FP-2 inhibition pharmacophore and fill better the S2 pocket may form potent FP-2 inhibitors (<xref rid="t0011" ref-type="table">Table 11</xref>).</p><p>The top scoring virtual hits are HLCIC analogues: 125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;H (<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>&#x02009;=&#x02009;30&#x02009;nM), 127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;H (<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>&#x02009;=&#x02009;30&#x02009;nM) without any specific P2 substitution; 125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;128 (<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>&#x02009;=&#x02009;13&#x02009;nM), 125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;129 (<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>&#x02009;=&#x02009;15&#x02009;nM), 127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;128 (<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>&#x02009;=&#x02009;13&#x02009;nM), 127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;129 (<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>&#x02009;=&#x02009;15&#x02009;nM), 125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;137 (<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>&#x02009;=&#x02009;16&#x02009;nM), and 127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;137 (<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>&#x02009;=&#x02009;15&#x02009;nM) with specific substitution targeting S2 pocket filling (<italic>R</italic>
<sub>6</sub> substituent). While the first set displays predicted potency approximately 200 times better than the training set (HLCIC1; <xref rid="t0010" ref-type="table">Table 10</xref>), the last set of new analogues reached <italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> 500 times better (<xref rid="t0011" ref-type="table">Table 11</xref>). Despite this exceedingly optimistic picture, our approach helped to identify interesting hydrophobic side chains (<italic>R</italic>
<sub>6</sub>-groups) such as (tetrahydro-2H-pyran)Me (128), (piperidin-4-yl)Me (129) and <italic>n</italic>-butane (137) for the S2 pocket filling with a bulkier group compared to the E64 which is decorated only with a short propyl chain at the P2 position. Indeed, from superimposition of the most active training set HLCIC (<xref ref-type="fig" rid="F0009">Figure 9(a)</xref>) and the less active ones (<xref ref-type="fig" rid="F0009">Figure 9(b)</xref>), we can see that E64 remains the only inhibitor to map the S2 pocket. The superimposition of the best-designed analogues (<xref ref-type="fig" rid="F0010">Figure 10</xref>) highlights the significance of hydrophobic contact with the S2 pocket. In fact, an additional pharmacophore derived from these new HLCIC analogues suggests an additional hydrophobic feature located at the S2 pocket (<xref ref-type="fig" rid="F0011">Figure 11</xref>). <xref ref-type="fig" rid="F0012">Figure 12</xref> shows the interactions of one of the best-designed analogues 125&#x02013;1-1&#x02013;H&#x02013;lki-128 (<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>&#x02009;=&#x02009;13&#x02009;nM) with the FP-2 and the Connolly surface of the binding site shows the lipophilic S2 pocket accommodating a bulkier substituent contributing to better stabilisation and greater affinity. These results are in good agreement with the reported structural information from experimental structure&#x02013;activity relationship on FP-2 and FP-3 pyrimidine-carbonitrile inhibitors<xref rid="CIT0045" ref-type="bibr">
<sup>45</sup>
</xref> as well as QSAR model and <italic>in silico</italic> design of dipeptide nitriles inhibitors of FP-3<xref rid="CIT0026" ref-type="bibr">
<sup>26</sup>
</xref> and FP-2<xref rid="CIT0046" ref-type="bibr">
<sup>46</sup>
</xref>. These conclusions are also in line with the recent SAR study on synthesis and molecular docking of coumarin containing pyrazoline derivatives as promising inhibitors of <italic>in vitro</italic> development of a chloroquine-sensitive (MRC-02) and chloroquine-resistant (RKL-2) strain of <italic>Pf</italic>
<xref rid="CIT0047" ref-type="bibr">
<sup>47</sup>
</xref>.</p><fig id="F0009" orientation="portrait" position="float"><label>Figure 9.</label><caption><p>(a) Superposition of most active training set HLClC inhibitors in bound conformation to crystallographic E64 (E64-RX: yellow; HLCIC1: green; HLCIC2: red; HLCIC7: violet; HLCIC13: blue; HLCIC14: orange). (b) Same superposition of less active training set HLClC (E64-RX: yellow; HLCIC4: white; HLCIC8: cyan; HLCIC6: brown).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1564288_F0009_C"/></fig><fig id="F0010" orientation="portrait" position="float"><label>Figure 10.</label><caption><p>Superimposition of the best analogues exploring the S2 pocket of FP-2 active site; 125&#x02013;1-1-H-lki-128 (green, <italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> = 13&#x02009;nM), 125&#x02013;1-1-H-lki-129 (red, <italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> = 15&#x02009;nM), 125&#x02013;1-1-H-lki-134 (orange, <italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> = 18&#x02009;nM), 127&#x02013;1-1-H-lki-128 (purple, <italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> = 13&#x02009;nM), 127&#x02013;1-1-H-lki-129 (blue, <italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> = 15&#x02009;nM), 127&#x02013;1-1-H-lki-134 (white, <italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> = 15&#x02009;nM).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1564288_F0010_C"/></fig><fig id="F0011" orientation="portrait" position="float"><label>Figure 11.</label><caption><p>The inhibition pharmacophore filling the S2 pocket of the FP-2 active site derived from the bound conformation of the best analogues with P2 substitution such as 125&#x02013;1-1-H-lki-128 (<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>=13&#x02009;nM) (green): distances (a), angles (b), features (c), and 125&#x02013;1-1-H-lki-128 mapping (d). Compared with the 3D QSAR complexation PH4, a supplementary hydrophobic feature corresponding to S2 pocket filling appeared. The features are coloured blue for hydrophobic aliphatic (HYd), green for hydrogen-bond acceptor (HBA), purple for hydrogen-bond donor (HBD) and orange for aromatic (Ar). The arrows represent the projection for the donor and acceptor features.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1564288_F0011_C"/></fig><fig id="F0012" orientation="portrait" position="float"><label>Figure 12.</label><caption><p>P2 substitution for the S2 pocket filling. (Left): Close up of 125&#x02013;1-1&#x02013;H&#x02013;lki&#x02013;128 (<italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> = 13&#x02009;nM) at the FP-2 active site. Carbon atoms of interacting residue side chains are coloured blue and those of ligand in green. (Right): Connolly surface of the FP-2 active site for 125&#x02013;1-1&#x02013;H&#x02013;lki&#x02013;128. The binding site surface is coloured according to residue hydrophobicity: red &#x02013; hydrophobic, blue &#x02013; hydrophilic and white &#x02013; intermediate.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1564288_F0012_C"/></fig><p>The ADME-related properties were also computed for the best active designed HLCIC as well as for drug used for the treatment of malaria (<xref rid="t0012" ref-type="table">Table 12</xref>). The chief descriptor, the number of stars (*) deviation of the computed values from the optimum ranges for 95% of known drugs is close to those for known antimalarials. It can be noticed that the human oral absorption in gastrointestinal tract (HOA) is low for the new HLCIC analogues suggesting non-oral delivery. The blood&#x02013;brain barrier descriptor is in the appropriate range.</p><table-wrap id="t0012" orientation="landscape" position="float"><label>Table 12.</label><caption><p>Predicted ADME-related properties of the best designed HLCIC analogues and known antimalarial agents either in clinical use or currently undergoing clinical testing, as computed by QikProp<xref rid="CIT0034" ref-type="bibr">
<sup>34</sup>
</xref>
</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">No</th><th align="center">Molecules<xref ref-type="table-fn" rid="TF25">
<sup>a</sup>
</xref></th><th align="center">#stars<xref ref-type="table-fn" rid="TF26">
<sup>b</sup>
</xref></th><th align="center">MW [g.mol<sup>&#x02212;1</sup>]<xref ref-type="table-fn" rid="TF27">
<sup>c</sup>
</xref></th><th align="center">Smol [A<sup>2</sup>]<xref ref-type="table-fn" rid="TF28">
<sup>d</sup>
</xref></th><th align="center">Smol, hfo<xref ref-type="table-fn" rid="TF29">
<sup>e</sup>
</xref> [&#x000c5;<sup>2</sup>]</th><th align="center">Vmol [&#x000c5;<sup>3</sup>]<xref ref-type="table-fn" rid="TF30">
<sup>f</sup>
</xref></th><th align="center">RotB<xref ref-type="table-fn" rid="TF31">
<sup>g</sup>
</xref></th><th align="center">HBdon<xref ref-type="table-fn" rid="TF32">
<sup>h</sup>
</xref></th><th align="center">HBacc<xref ref-type="table-fn" rid="TF33">
<sup>i</sup>
</xref></th><th align="center">logPo/w<xref ref-type="table-fn" rid="TF34">
<sup>j</sup>
</xref></th><th align="center">logSwat<xref ref-type="table-fn" rid="TF35">
<sup>k</sup>
</xref></th><th align="center">BIPcaco<xref ref-type="table-fn" rid="TF36">
<sup>l</sup>
</xref> [nm.s<sup>&#x02212;1</sup>]</th><th align="center">logB/B<xref ref-type="table-fn" rid="TF37">
<sup>m</sup>
</xref></th><th align="center">#meta<xref ref-type="table-fn" rid="TF38">
<sup>n</sup>
</xref></th><th align="center">logKHSA<xref ref-type="table-fn" rid="TF39">
<sup>o</sup>
</xref></th><th align="center">HOA<xref ref-type="table-fn" rid="TF40">
<sup>p</sup>
</xref></th><th align="center">%HOA<xref ref-type="table-fn" rid="TF41">
<sup>q</sup>
</xref></th><th align="center"><italic>IC</italic><sub>50</sub><sup>pred</sup><xref ref-type="table-fn" rid="TF42">
<sup>r</sup>
</xref> [nM]</th></tr></thead><tbody valign="top"><tr><td align="left">31</td><td align="left">125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;H</td><td align="center">7</td><td align="center">686.0</td><td align="char" char=".">1011</td><td align="center">123.2</td><td align="center">1899</td><td align="center">17</td><td align="center">5</td><td align="center">16</td><td align="center">2.2</td><td align="center">&#x02212;6.1</td><td align="center">2.2</td><td align="center">&#x02212;3.6</td><td align="center">4</td><td align="center">&#x02212;0.251</td><td align="center">1</td><td align="center">20.7</td><td align="center">30</td></tr><tr><td align="left">33</td><td align="left">127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;H</td><td align="center">5</td><td align="center">661.0</td><td align="char" char=".">989</td><td align="center">128.4</td><td align="center">1834</td><td align="center">16</td><td align="center">5</td><td align="center">15</td><td align="center">2.8</td><td align="center">&#x02212;5.3</td><td align="center">11.5</td><td align="center">&#x02212;2.7</td><td align="center">5</td><td align="center">&#x02212;0.196</td><td align="center">1</td><td align="center">36.6</td><td align="center">30</td></tr><tr><td align="left">82</td><td align="left">125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;128</td><td align="center">11</td><td align="center">784,2</td><td align="char" char=".">1135</td><td align="center">371,1</td><td align="center">2266</td><td align="center">19</td><td align="center">5</td><td align="center">18</td><td align="center">4,1</td><td align="center">&#x02212;7,2</td><td align="center">7,6</td><td align="center">&#x02212;3,1</td><td align="center">6</td><td align="center">0,253</td><td align="center">1</td><td align="center">40.9</td><td align="center">13</td></tr><tr><td align="left">83</td><td align="left">125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;129</td><td align="center">12</td><td align="center">783,2</td><td align="char" char=".">1178</td><td align="center">294,2</td><td align="center">2238</td><td align="center">19</td><td align="center">6</td><td align="center">17</td><td align="center">2,6</td><td align="center">&#x02212;6,7</td><td align="center">0,2</td><td align="center">&#x02212;4,2</td><td align="center">5</td><td align="center">0,104</td><td align="center">1</td><td align="center">0</td><td align="center">15</td></tr><tr><td align="left">84</td><td align="left">125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;134</td><td align="center">12</td><td align="center">772.2</td><td align="char" char=".">1230</td><td align="center">303.4</td><td align="center">2290</td><td align="center">22</td><td align="center">6</td><td align="center">18</td><td align="center">3.0</td><td align="center">&#x02212;8.2</td><td align="center">0.3</td><td align="center">&#x02212;5.8</td><td align="center">6</td><td align="center">0.024</td><td align="center">1</td><td align="center">0</td><td align="center">18</td></tr><tr><td align="left">88</td><td align="left">127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;128</td><td align="center">8</td><td align="center">759.2</td><td align="char" char=".">1078</td><td align="center">282.8</td><td align="center">2099</td><td align="center">18</td><td align="center">5</td><td align="center">17</td><td align="center">3.8</td><td align="center">&#x02212;5.8</td><td align="center">16.2</td><td align="center">&#x02212;2.6</td><td align="center">7</td><td align="center">0.068</td><td align="center">1</td><td align="center">45.1</td><td align="center">13</td></tr><tr><td align="left">89</td><td align="left">127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;129</td><td align="center">8</td><td align="center">758.2</td><td align="char" char=".">1114</td><td align="center">291.2</td><td align="center">2130</td><td align="center">18</td><td align="center">6</td><td align="center">16</td><td align="center">3.2</td><td align="center">&#x02212;5.1</td><td align="center">2.4</td><td align="center">&#x02212;2.6</td><td align="center">6</td><td align="center">0.098</td><td align="center">1</td><td align="center">13.7</td><td align="center">15</td></tr><tr><td align="left">90</td><td align="left">127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;134</td><td align="center">8</td><td align="center">747.1</td><td align="char" char=".">1091</td><td align="center">233.0</td><td align="center">2096</td><td align="center">21</td><td align="center">6</td><td align="center">17</td><td align="center">3.3</td><td align="center">&#x02212;5.4</td><td align="center">5.3</td><td align="center">&#x02212;3.5</td><td align="center">7</td><td align="center">&#x02212;0.13</td><td align="center">1</td><td align="center">20.4</td><td align="center">17</td></tr><tr><td align="left">93</td><td align="left">122&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;130</td><td align="center">10</td><td align="center">824.3</td><td align="char" char=".">1190</td><td align="center">382.5</td><td align="center">2292</td><td align="center">18</td><td align="center">5</td><td align="center">15</td><td align="center">5.6</td><td align="center">&#x02212;7.3</td><td align="center">7.5</td><td align="center">&#x02212;1.9</td><td align="center">6</td><td align="center">0.80</td><td align="center">1</td><td align="center">36.3</td><td align="center">26</td></tr><tr><td align="left">109</td><td align="left">125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;132</td><td align="center">9</td><td align="center">728.2</td><td align="char" char=".">1082</td><td align="center">258.3</td><td align="center">2040</td><td align="center">18</td><td align="center">5</td><td align="center">16</td><td align="center">3.2</td><td align="center">&#x02212;7.1</td><td align="center">3.3</td><td align="center">&#x02212;3.7</td><td align="center">5</td><td align="center">0.01</td><td align="center">1</td><td align="center">28.8</td><td align="center">29</td></tr><tr><td align="left">110</td><td align="left">125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;133</td><td align="center">10</td><td align="center">742.2</td><td align="char" char=".">1128</td><td align="center">291.1</td><td align="center">2122</td><td align="center">19</td><td align="center">5</td><td align="center">16</td><td align="center">3.5</td><td align="center">&#x02212;7.7</td><td align="center">2.3</td><td align="center">&#x02212;4.1</td><td align="center">5</td><td align="center">0.15</td><td align="center">1</td><td align="center">27.9</td><td align="center">20</td></tr><tr><td align="left">111</td><td align="left">125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;137</td><td align="center">11</td><td align="center">742.2</td><td align="char" char=".">1141</td><td align="center">310.9</td><td align="center">2138</td><td align="center">20</td><td align="center">5</td><td align="center">16</td><td align="center">3.6</td><td align="center">&#x02212;7.8</td><td align="center">2.4</td><td align="center">&#x02212;4.2</td><td align="center">5</td><td align="center">0.14</td><td align="center">1</td><td align="center">29.1</td><td align="center">16</td></tr><tr><td align="left">112</td><td align="left">127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;132</td><td align="center">5</td><td align="center">703.1</td><td align="char" char=".">1041</td><td align="center">240.4</td><td align="center">1975</td><td align="center">17</td><td align="center">5</td><td align="center">15</td><td align="center">3.8</td><td align="center">&#x02212;6.0</td><td align="center">19.1</td><td align="center">&#x02212;2.5</td><td align="center">6</td><td align="center">0.10</td><td align="center">1</td><td align="center">46.3</td><td align="center">23</td></tr><tr><td align="left">113</td><td align="left">127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;133</td><td align="center">6</td><td align="center">717.2</td><td align="char" char=".">1072</td><td align="center">270.3</td><td align="center">2040</td><td align="center">18</td><td align="center">5</td><td align="center">15</td><td align="center">4.2</td><td align="center">&#x02212;6.3</td><td align="center">19.2</td><td align="center">&#x02212;2.6</td><td align="center">6</td><td align="center">0.21</td><td align="center">1</td><td align="center">48.6</td><td align="center">19</td></tr><tr><td align="left">114</td><td align="left">127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;137</td><td align="center">6</td><td align="center">717.2</td><td align="char" char=".">1080</td><td align="center">273.6</td><td align="center">2046</td><td align="center">19</td><td align="center">5</td><td align="center">15</td><td align="center">4.2</td><td align="center">&#x02212;6.3</td><td align="center">17.5</td><td align="center">&#x02212;2.7</td><td align="center">6</td><td align="center">0.17</td><td align="center">1</td><td align="center">47.8</td><td align="center">15</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Amodiaquine</td><td align="center">1</td><td align="center">333.7</td><td align="char" char=".">603</td><td align="center">131.7</td><td align="center">1019</td><td align="center">6</td><td align="center">0</td><td align="center">5</td><td align="center">3.6</td><td align="center">&#x02212;4.8</td><td align="center">1689</td><td align="center">&#x02212;0.4</td><td align="center">0</td><td align="center">0.0</td><td align="center">3</td><td align="center">100.0</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Arteether</td><td align="center">1</td><td align="center">312.4</td><td align="char" char=".">531</td><td align="center">506.0</td><td align="center">970</td><td align="center">2</td><td align="center">0</td><td align="center">6</td><td align="center">2.7</td><td align="center">&#x02212;3.1</td><td align="center">5731.8</td><td align="center">0.2</td><td align="center">0</td><td align="center">&#x02212;0.2</td><td align="center">3</td><td align="center">100.0</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Artemether</td><td align="center">1</td><td align="center">298.4</td><td align="char" char=".">491</td><td align="center">465.5</td><td align="center">902</td><td align="center">1</td><td align="center">0</td><td align="center">6</td><td align="center">2.3</td><td align="center">&#x02212;2.9</td><td align="center">5729</td><td align="center">0.3</td><td align="center">0</td><td align="center">&#x02212;0.3</td><td align="center">3</td><td align="center">100.0</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Artemisinin</td><td align="center">0</td><td align="center">282</td><td align="char" char=".">457</td><td align="center">380.6</td><td align="center">848</td><td align="center">0</td><td align="center">0</td><td align="center">5</td><td align="center">1.7</td><td align="center">&#x02212;2.1</td><td align="center">1886</td><td align="center">0.1</td><td align="center">1</td><td align="center">&#x02212;0.3</td><td align="center">3</td><td align="center">95.8</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Art&#x000e9;sunate</td><td align="center">0</td><td align="center">384.4</td><td align="char" char=".">644</td><td align="center">465.1</td><td align="center">1156</td><td align="center">4</td><td align="center">1</td><td align="center">8</td><td align="center">2.5</td><td align="center">&#x02212;3.9</td><td align="center">50.4</td><td align="center">&#x02212;1.4</td><td align="center">2</td><td align="center">&#x02212;0.1</td><td align="center">3</td><td align="center">72.0</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Dihydroart&#x000e9;misinine</td><td align="center">1</td><td align="center">284.4</td><td align="char" char=".">477</td><td align="center">395.7</td><td align="center">865</td><td align="center">1</td><td align="center">1</td><td align="center">6</td><td align="center">1.8</td><td align="center">&#x02212;2.8</td><td align="center">1664.9</td><td align="center">&#x02212;0.1</td><td align="center">0</td><td align="center">&#x02212;0.1</td><td align="center">3</td><td align="center">95.4</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Doxycycline</td><td align="center">4</td><td align="center">422.3</td><td align="char" char=".">602</td><td align="center">174.0</td><td align="center">1104</td><td align="center">2</td><td align="center">0</td><td align="center">17</td><td align="center">&#x02212;4.0*</td><td align="center">&#x02212;0.9</td><td align="center">9.2*</td><td align="center">&#x02212;2.5</td><td align="center">4</td><td align="center">&#x02212;2.9*</td><td align="center">1</td><td align="center">20.8</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Halofantrine</td><td align="center">5</td><td align="center">470.2</td><td align="char" char=".">785</td><td align="center">160.2</td><td align="center">1352</td><td align="center">5</td><td align="center">0</td><td align="center">3</td><td align="center">7.6*</td><td align="center">&#x02212;8.5*</td><td align="center">2844.1</td><td align="center">0.2</td><td align="center">0</td><td align="center">1.5</td><td align="center">1</td><td align="center">100.0</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">Lum&#x000e9;fantrine</td><td align="center">5</td><td align="center">496.7</td><td align="char" char=".">819</td><td align="center">160.7</td><td align="center">1438</td><td align="center">7</td><td align="center">0</td><td align="center">3</td><td align="center">8.3*</td><td align="center">&#x02212;9.4*</td><td align="center">4337.2</td><td align="center">0.2</td><td align="center">0</td><td align="center">1.7*</td><td align="center">1</td><td align="center">100.0</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">M&#x000e9;floquine</td><td align="center">2</td><td align="center">362.2</td><td align="char" char=".">533</td><td align="center">0.0</td><td align="center">925</td><td align="center">2</td><td align="center">0</td><td align="center">4</td><td align="center">4.1</td><td align="center">&#x02212;5.9</td><td align="center">2903.1</td><td align="center">0.5</td><td align="center">0</td><td align="center">0.1</td><td align="center">3</td><td align="center">100.0</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">T&#x000e9;tracycline</td><td align="center">5</td><td align="center">422.3</td><td align="char" char=".">605</td><td align="center">173.1</td><td align="center">1112</td><td align="center">2</td><td align="center">0</td><td align="center">16</td><td align="center">&#x02212;3.4*</td><td align="center">&#x02212;1.4</td><td align="center">6.8*</td><td align="center">&#x02212;2.6</td><td align="center">5</td><td align="center">&#x02212;2.5*</td><td align="center">1</td><td align="center">21.8*</td><td align="center">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TF25"><p>
<sup>a</sup>Designed analogues (<xref rid="t0010" ref-type="table">Table 10</xref>).</p></fn><fn id="TF26"><p>
<sup>b</sup>Drug likeness, number of property descriptors (from 24 out of the full list of 49 descriptors of QikProp, version 3.7, release 14) that fall outside of the range of values for 95% of known drugs.</p></fn><fn id="TF27"><p>
<sup>c</sup>Molecular weight in g.mol<sup>&#x02212;1</sup> (range for 95% of drugs: 130&#x02013;725&#x02009;g.mol<sup>&#x02212;1</sup>).</p></fn><fn id="TF28"><p>
<sup>d</sup>Total solvent-accessible molecular surface, in &#x000c5;<sup>2</sup> (probe radius 1.4&#x02009;&#x000c5;) (range for 95% of drugs: 300&#x02013;1000 &#x000c5;<sup>2</sup>).</p></fn><fn id="TF29"><p>
<sup>e</sup>Hydrophobic portion of the solvent-accessible molecular surface, in &#x000c5;<sup>2</sup> (probe radius 1.4&#x02009;&#x000c5;) (range for 95% of drugs: 0&#x02013;750 &#x000c5;<sup>2</sup>).</p></fn><fn id="TF30"><p>
<sup>f</sup>Total volume of molecule enclosed by solvent-accessible molecular surface, in &#x000c5;<sup>3</sup> (probe radius 1.4&#x02009;&#x000c5;) (range for 95% of drugs: 500&#x02013;2000 &#x000c5;<sup>3</sup>).</p></fn><fn id="TF31"><p>
<sup>g</sup>Number of non-trivial (not CX3), non-hindered (not alkene, amide, small ring) rotatable bonds (range for 95% of drugs: 0&#x02013;15).</p></fn><fn id="TF32"><p>
<sup>h</sup>Estimated number of hydrogen bonds that could be donated by the solute to water molecules in solution, averaged over a number of configurations (range for 95% of drugs: 0.0&#x02013;6.0).</p></fn><fn id="TF33"><p>
<sup>i</sup>Estimated number of hydrogen bonds that could be accepted by the solute from water molecules, averaged taken over a number of configurations (range for 95% of drugs: 2.0&#x02013;20.0).</p></fn><fn id="TF34"><p>
<sup>j</sup>Logarithm of partitioning coefficient between <italic>n</italic>-octanol and water phases (range for 95% of drugs: &#x02212;2 to 6.5).</p></fn><fn id="TF35"><p>
<sup>k</sup>Logarithm of predicted aqueous solubility, log S. S in mol&#x022c5;dm<sup>&#x02212;3</sup> is the concentration of the solute in a saturated solution that is in equilibrium with the crystalline solid (range for 95% of drugs: &#x02212;6.0 to 0.5).</p></fn><fn id="TF36"><p>
<sup>l</sup>Predicted apparent Caco-2 cell membrane permeability in Boehringer-Ingelheim scale, in [nm&#x022c5;s <sup>&#x02212;1</sup>] (range for 95% of drugs: &#x0003c;25 poor, &#x0003e;500 great).</p></fn><fn id="TF37"><p>
<sup>m</sup>Logarithm of predicted brain/blood partition coefficient. (range for 95% of drugs: &#x02212;3.0 to 1.2).</p></fn><fn id="TF38"><p>
<sup>n</sup>Number of likely metabolic reactions (range for 95% of drugs: 1&#x02013;8).</p></fn><fn id="TF39"><p>
<sup>o</sup>Logarithm of predicted binding constant to human serum albumin (range for 95% of drugs: &#x02212;1.5 to 1.5).</p></fn><fn id="TF40"><p>
<sup>p</sup>Human oral absorption (1: low; 2: medium; 3: high).</p></fn><fn id="TF41"><p>
<sup>q</sup>Percentage of human oral absorption in gastrointestinal tract (&#x0003c;25% poor, &#x0003e;80% high).</p></fn><fn id="TF42"><p>
<sup>r</sup>Predicted inhibition constants <italic>IC</italic>
<sub>50</sub>
<sup>pre</sup>. <italic>IC</italic>
<sub>50</sub>
<sup>pre</sup> was predicted from computed &#x00394;&#x00394;<italic>G</italic>
<sub>com</sub> using the regression equation shown in <xref rid="t0003" ref-type="table">Table 3</xref>.</p></fn><fn id="TF43"><p>*Asterisk indicates that the property descriptor value falls outside the range of values for 95% of known drugs.</p></fn></table-wrap-foot></table-wrap></sec></sec></sec><sec id="s0020"><label>4.</label><title>Conclusion</title><p>Natural-product-like hybrids design for <italic>pf</italic>FP-2 inhibition stems from the multiple need to provide naturally occurring, resistance overcoming, and favourable pharmacokinetic profile compounds mimicking in this way, how nature synthesise by exploring efficiently chemical space. HLCIC antimalarials structural requirement for falcipain 2 inhibition has been assessed from the complexation &#x0201c;one descriptor&#x0201d; QSAR correlating GFE upon <italic>pf</italic>FP-2:HLCIC complex formation with activity. Moreover the derived 3D QSAR Pharmacophore was augmented to S2 pocket filling in order to provide a complete PH4 able to guide synthesis of novel potent isatin&#x02013;chalcone inhibitors. Virtual screening of large and diverse VL of HLCIC analogues by the PH4 led to identification of 125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;H (30&#x02009;nM), 127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;H (30&#x02009;nM) 125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;128 (13&#x02009;nM), 125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;129 (15&#x02009;nM), 127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;128 (13&#x02009;nM), 127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;129 (15&#x02009;nM), 125&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;137 (16&#x02009;nM) and 127&#x02013;1&#x02013;1&#x02013;H&#x02013;lki&#x02013;137 (15&#x02009;nM); the best ones according to our design strategy based on S2 hydrophobic contact display predicted potency reaching 200 times that of the most active training set HLCIC1. They are recommended for synthesis and evaluation to check the efficiency of our design approach and guide future discovery of non-peptide, natural product like hybrids FP-2 inhibitors.</p></sec></body><back><sec id="s0021"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>OMS</collab></person-group> World malaria report 2016. <year>2016</year>.</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="web">Status report on artemisinin and ACT resistance September 2015. <year>2015</year> Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/malaria/publications/atoz/status-rep-artemisinin-resistance-sept2015.pdf">http://www.who.int/malaria/publications/atoz/status-rep-artemisinin-resistance-sept2015.pdf</ext-link> [last accessed 28 Jul 2017].</mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="web">
<person-group person-group-type="author"><collab>Foods and Drugs Authority &#x02013; FDA GHANA</collab></person-group>
<year>2015</year> Available from: <ext-link ext-link-type="uri" xlink:href="https://fdaghana.gov.gh/records/">https://fdaghana.gov.gh/records/</ext-link>.</mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hartwig</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Lauterwasser</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Mahajan</surname><given-names>SS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Investigating the antimalarial action of 1, 2, 4-trioxolanes with fluorescent chemical probes</article-title>. <source>J Med Chem</source>
<year>2011</year>;<volume>54</volume>:<fpage>156</fpage>&#x02013;<lpage>67</lpage>.</mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Ackerman</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>XZ</given-names></name>, <name name-style="western"><surname>Wellems</surname><given-names>TE</given-names></name></person-group>
<article-title>Malaria biology and disease pathogenesis: insights for new treatments</article-title>. <source>Nat Med</source>
<year>2013</year>;<volume>19</volume>:<fpage>156</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">23389616</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Mohanakrishnan</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Shard</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Stilbene-chalcone hybrids: design, synthesis and evaluation as a new class of antimalarial scaffolds that trigger cell death through stage specific apoptosis</article-title>. <source>J Med Chem</source>
<year>2012</year>;<volume>55</volume>:<fpage>297</fpage>&#x02013;<lpage>311</lpage>.<pub-id pub-id-type="pmid">22098429</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Capela</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Oliveira</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Goncalves</surname><given-names>LM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Artemisinin-dipeptidyl vinyl sulfone hybrid molecules: design, synthesis and preliminary SAR for antiplasmodial activity and falcipain-2 inhibition</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2009</year>;<volume>19</volume>:<fpage>3229</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">19435664</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>N'Guessan</surname><given-names>AJB</given-names></name>, <name name-style="western"><surname>Megnassan</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ziao</surname><given-names>N</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Artemisinin-dipeptidyl vinyl sulfone hybrid inhibitors of <italic>Plasmodium falciparum</italic> falcipain 2 with favorable pharmacokinetic profile</article-title>. <source>J Drug Des Devel</source>
<year>2017</year>;<volume>1</volume>:<fpage>11</fpage>&#x02013;<lpage>28</lpage>.</mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Grelb</surname><given-names>MH</given-names></name></person-group>
<article-title>Drug discovery for malaria: a very challenging and timely endeavor</article-title>. <source>Curr Opin Chem Biol</source>
<year>2007</year>;<volume>11</volume>:<fpage>440</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">17761335</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bekono</surname><given-names>BD</given-names></name>, <name name-style="western"><surname>Ntie-Kang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Owono</surname><given-names>OLC</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Targeting cysteine proteases from <italic>Plasmodium falciparum</italic>: a general overview, rational drug design and computational approaches for drug discovery</article-title>. <source>Curr Drug Targets</source>
<year>2018</year>;<volume>19</volume>:<fpage>501</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">28003005</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Teixeira</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gomes</surname><given-names>JRB</given-names></name>, <name name-style="western"><surname>Gomes</surname><given-names>P</given-names></name></person-group>
<article-title>Falcipains, <italic>Plasmodium falciparum</italic> cysteine proteases as key drug targets against malaria</article-title>. <source>Curr Med Chem</source>
<year>2011</year>;<volume>18</volume>:<fpage>1555</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">21428877</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hans</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Gut</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rosenthal</surname><given-names>PJ</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Comparison of the antiplasmodial and falcipain-2 inhibitory activity of b-amino alcohol thiolactone-chalcone and isatin-chalcone hybrids</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2010</year>;<volume>20</volume>:<fpage>2234</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">20206517</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Subramanian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sijwali</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Rosenthal</surname><given-names>PJ</given-names></name></person-group>
<article-title>Falcipain cysteine proteases require bipartite motifs for trafficking to the <italic>Plasmodium falciparum</italic> food vacuole</article-title>. <source>J Biol Chem</source>
<year>2007</year>;<volume>282</volume>:<fpage>24961</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">17565983</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hogg</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Nagarajan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Herzberg</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structural and Functional Characterization of Falcipain-2, a Hemoglobin from the Malaria Parasite <italic>Plasmodium falciparum</italic>
</article-title>. <source>J Biol Chem</source>
<year>2006</year>;<volume>281</volume>:<fpage>25425</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">16777845</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kerr</surname><given-names>ID</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Pandey</surname><given-names>KC</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structures of falcipain-2 and falcipain-3 bound to small molecule inhibitors: implications for substrate specificity</article-title>. <source>J Med Chem</source>
<year>2009</year>;<volume>52</volume>:<fpage>852</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">19128015</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Frecer</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Kabelac</surname><given-names>M</given-names></name>, <name name-style="western"><surname>De Nardi</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus</article-title>. <source>J Mol Graph Model</source>
<year>2004</year>;<volume>22</volume>:<fpage>209</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">14629979</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Frecer</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Burello</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Miertus</surname><given-names>S</given-names></name></person-group>
<article-title>Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1</article-title>. <source>Bioorg Med Chem</source>
<year>2005</year>;<volume>13</volume>:<fpage>5492</fpage>&#x02013;<lpage>501</lpage>.<pub-id pub-id-type="pmid">16054372</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Frecer</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Berti</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Benedetti</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design of peptidomimetic inhibitors of aspartic protease of HIV-1 containing -Phe Psi Pro- core and displaying favourable ADME-related properties</article-title>. <source>J Mol Graph Model</source>
<year>2008</year>;<volume>27</volume>:<fpage>376</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">18678515</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Dali</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Keita</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Megnassan</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of <italic>Plasmodium falciparum</italic> over human cathepsin D</article-title>. <source>Chem Biol Drug Des</source>
<year>2012</year>;<volume>79</volume>:<fpage>411</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">22129033</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Megnassan</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Keita</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bieri</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design of novel dihydroxynaphthoic acid inhibitors of <italic>Plasmodium falciparum</italic> lactate dehydrogenase</article-title>. <source>Med Chem</source>
<year>2012</year>;<volume>8</volume>:<fpage>970</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">22741776</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Owono Owono</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Keita</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Megnassan</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design of thymidine analogues targeting thymidilate kinase of <italic>Mycobacterium tuberculosis</italic>
</article-title>. <source>Tuberc Res Treat</source>
<year>2013</year>;<volume>2013</volume>:<fpage>670836</fpage>.<pub-id pub-id-type="pmid">23634301</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Keita</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dali</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Quantitative structure-activity relationships and design of thymine-like inhibitors of thymidine monophosphate kinase of <italic>Mycobacterium tuberculosis</italic> with favourable pharmacokinetic profiles</article-title>. <source>RSC Adv</source>
<year>2014</year>;<volume>4</volume>:<fpage>55853</fpage>&#x02013;<lpage>66</lpage>.</mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Frecer</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Seneci</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Miertus</surname><given-names>S</given-names></name></person-group>
<article-title>Computer-assisted combinatorial design of bicyclic thymidine analogs as inhibitors of <italic>Mycobacterium tuberculosis</italic> thymidine monophosphate kinase</article-title>. <source>J Comput Aided Mol Des</source>
<year>2011</year>;<volume>25</volume>:<fpage>31</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">21082329</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Owono Owono</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Ntie-Kang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Keita</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Virtually designed triclosan-based inhibitors of enoyl-acyl carrier protein reductase of <italic>Mycobacterium tuberculosis</italic> and of <italic>Plasmodium falciparum</italic>
</article-title>. <source>Mol Inform</source>
<year>2015</year>;<volume>34</volume>:<fpage>292</fpage>&#x02013;<lpage>307</lpage>.<pub-id pub-id-type="pmid">27490275</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kouassi</surname><given-names>AF</given-names></name>, <name name-style="western"><surname>Kone</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Keita</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Computer-aided design of orally bioavailable pyrrolidine carboxamide inhibitors of enoyl-acyl carrier protein reductase of <italic>Mycobacterium tuberculosis</italic> with favorable pharmacokinetic profiles</article-title>. <source>Int J Mol Sci</source>
<year>2015</year>;<volume>16</volume>:<fpage>29744</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">26703572</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Esmel</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Keita</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Megnassan</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Insight into binding mode of nitrile inhibitors of <italic>Plasmodium falciparum</italic> Falcipain-3, QSAR and Pharmacophore models, virtual design of new analogues with favorable pharmacokinetic profiles</article-title>. <source>J Comput Chem Molec Model</source>
<year>2017</year>;<volume>2</volume>:<fpage>103</fpage>&#x02013;<lpage>24</lpage>.</mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>Insight-II</collab></person-group>
<source>Insight-II and Discover molecular modeling and simulation package, Version 2005</source>. <publisher-loc>San Diego, CA</publisher-loc>: <publisher-name>Accelrys, Inc</publisher-name>; <year>2005</year>.</mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gilson</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Honig</surname><given-names>B</given-names></name></person-group>
<article-title>The inclusion of electrostatic hydration energies in molecular mechanics calculations</article-title>. <source>J Comput Aided Mol Des</source>
<year>1991</year>;<volume>5</volume>:<fpage>5</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">2072125</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rocchia</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Sridharan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nicholls</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Rapid grid-based construction of the molecular surface and the use of induced surface charge to calculate reaction field energies: applications to the molecular systems and geometric objects</article-title>. <source>J Comput Chem</source>
<year>2002</year>;<volume>23</volume>:<fpage>128</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">11913378</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="book">
<source>Discovery Studio molecular modeling and simulation program. Version 2.5</source>. <publisher-loc>San Diego, CA</publisher-loc>: <publisher-name>Accelrys, Inc</publisher-name>; <year>2009</year>.</mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>B&#x000f6;ttcher</surname><given-names>CJF</given-names></name></person-group>, <source>Theory of electric polarization</source>. <publisher-loc>Amsterdam, Netherlands</publisher-loc>: <publisher-name>Elsevier</publisher-name>; <year>1973</year>.</mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Miertus</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Scrocco</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Tomasi</surname><given-names>J</given-names></name></person-group>
<article-title>Electrostatic interaction of a solute with a continuum. A direct utilization of <italic>ab initio</italic> molecular potentials for the prevision of solvent effects</article-title>. <source>Chem Phys</source>
<year>1981</year>;<volume>55</volume>:<fpage>117</fpage>&#x02013;<lpage>29</lpage>.</mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sutter</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hoffmann</surname><given-names>R.</given-names></name></person-group> Pharmacophore perception development and use in drug design. In: G&#x000fc;ner OF, ed. hypoGen: an automated system for generating 3D predictive pharmacophore model. La Jolla, CA: International University Line; 2000. </mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>QikProp</collab></person-group>
<source>QikProp Version 3.7, Release 14</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>X Schr&#x000f6;dinger, LLC</publisher-name>; <year>2014</year>.</mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Duffy</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Jorgensen</surname><given-names>WL</given-names></name></person-group>
<article-title>Prediction of properties from simulations: free energies of solvation in hexadecane, octanol, and water</article-title>. <source>J Am Chem Soc</source>
<year>2000</year>;<volume>122</volume>:<fpage>2878</fpage>&#x02013;<lpage>88</lpage>.</mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jorgensen</surname><given-names>WL</given-names></name>, <name name-style="western"><surname>Duffy</surname><given-names>EM</given-names></name></person-group>
<article-title>Prediction of drug solubility from Monte Carlo simulations</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2000</year>;<volume>10</volume>:<fpage>1155</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">10866370</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jorgensen</surname><given-names>WL</given-names></name>, <name name-style="western"><surname>Duffy</surname><given-names>EM</given-names></name></person-group>
<article-title>Prediction of drug solubility from structure</article-title>. <source>Adv Drug Deliv Rev</source>
<year>2002</year>;<volume>54</volume>:<fpage>355</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">11922952</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>MOE</collab></person-group>
<source>Molecular Operating Environment (MOE); H3A 2R7</source>. <publisher-loc>Montreal, QC</publisher-loc>,: <publisher-name>Chemical Computing Group Inc</publisher-name>; <year>2014</year>
</mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Maple</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Hwang</surname><given-names>M-J</given-names></name>, <name name-style="western"><surname>Stockfisch</surname><given-names>TP</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Derivation of class II force fields. I. Methodology and quantum force field for the alkyl functional group and alkane molecules</article-title>. <source>J Comput Chem</source>
<year>1994</year>;<volume>15</volume>:<fpage>162</fpage>&#x02013;<lpage>82</lpage>.</mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Willett</surname><given-names>P.</given-names></name></person-group> Molecular similarity in drug design. In: Dean PM, ed. Similarity-searching and clustering algorithms for processing databases of two-dimensional and three-dimensional chemical structures. Glasgow, UK: Chapman and Hall; <year>1994</year>:<fpage>110</fpage>&#x02013;<lpage>137</lpage>.</mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lipinski</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Lombardo</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Dominy</surname><given-names>BW</given-names></name>, <name name-style="western"><surname>Feeney</surname><given-names>PJ</given-names></name></person-group>
<article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title>. <source>Adv Drug Deliv Rev</source>
<year>2001</year>;<volume>46</volume>:<fpage>3</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">11259830</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Schechter</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Berger</surname><given-names>A</given-names></name></person-group>
<article-title>On the size of the active site in proteases. I. Papain</article-title>. <source>Biochem Biophys Res Commun</source>
<year>1967</year>;<volume>27</volume>:<fpage>157</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">6035483</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Freire</surname><given-names>E</given-names></name></person-group>
<article-title>Do enthalpy and entropy distinguish first in class from best in class</article-title>. <source>Drug Discov Today</source>
<year>2008</year>;<volume>13</volume>:<fpage>869</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">18703160</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>N'Guessan</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Megnassan</surname><given-names>E</given-names></name></person-group>
<article-title>
<italic>In silico</italic> design of phosphonic arginine and hydroxamic acid inhibitors of <italic>Plasmodium falciparum</italic> M17 leucyl aminopeptidase with favorable pharmacokinetic profile</article-title>. <source>J Drug Design Med Chem</source>
<year>2017</year>;<volume>3</volume>:<fpage>86</fpage>&#x02013;<lpage>113</lpage>.</mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cotereon</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Catterick</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Castro</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Falcipain inhibitors: optimization studies of the 2-pyrimidine-carbonitrile lead series</article-title>. <source>J Med Chem</source>
<year>2010</year>;<volume>53</volume>:<fpage>6129</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">20672841</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fagnidi</surname><given-names>YKH</given-names></name>, <name name-style="western"><surname>Toi</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Megnassan</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>
<italic>In silico</italic> design of <italic>Plasmodium falciparum</italic> cysteine protease falcipain 2 inhibitors with favorable pharmacokinetic profile</article-title>. <source>J Anal Pharm Res</source>
<year>2018</year>;<volume>7</volume>:<fpage>298&#x02013;309</fpage>.</mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Himangini</surname><given-names>PDP</given-names></name>, <name name-style="western"><surname>Vidushi</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Designing novel inhibitors against falcipain-2 of <italic>Plasmodium falciparum</italic>
</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2018</year>;<volume>28</volume>:<fpage>1566</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">29602682</pub-id></mixed-citation></ref></ref-list></back></article>